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ABSTRACT
Kyna M. Gooden:  The Relationship between Uterine Leiomyomata and Polymorphsims of 
Cytochrome P-450 1A1, Cytochrome P-450 1B1, and Catechol-O-Methyltransferase
(Under the direction of Jane C. Schroeder)
Uterine leiomyomata, or fibroids, are one of the most common neoplasms in women of 
reproductive age.  They occur more often and are larger in African American women compared 
to White women.  Although benign, the etiology of fibroids is largely unknown, however they 
are hormonally dependent.  The biologic effect of estrogen is influenced by estrogen metabolism; 
therefore estrogen metabolism enzymes may influence fibroid development.  Cytochrome P-450 
1A1 (CYP1A1), Cytochrome P-450 1B1 (CYP1B1), and Catechol-O-Methyltransferase (COMT)
are polymorphic genes that encode key enzymes in the estrogen metabolism pathway.  Four 
single nucleotide polymorphisms (SNP) of CYP1A1, 2 SNPs of CYP1B1, and 1 SNP of COMT
were evaluated for associations with fibroid prevalence and size in a cross-sectional sample of 
premenopausal African American (n=583) and White (n=404) women from the National Institute 
of Environmental Health Sciences Uterine Fibroid Study.  Participants provided DNA samples 
and completed telephone interviews and questionnaires.  Race-specific prevalence ratios (PR) 
and 95% confidence intervals (CI) were estimated from log-risk regression models; prevalence 
differences (PD) and 95% CI were estimated from linear-risk regression models.  Haplotypes and 
diplotypes were inferred for CYP1A1 and CYP1B1.  Genotype distributions varied by race.  
African Americans were more likely to have fibroids (72% vs 50%) and to have large fibroids 
(24% vs 11%) than Whites.  The CYP1A1*3allele was associated with fibroids among African 
Americans (PR=1.14; 95%CI: 1.02, 1.28; PD=0.10; 95%CI: 0.01, 0.19).  The CYP1A1*4 allele
was positively associated with fibroids among both Whites (PR=1.20; 95%CI: 0.90, 1.61; 
iv
PD=0.10; 95%CI: -0.07, 0.27) and African Americans (PR=1.16; 95%CI: 0.92, 1.48; PD=0.12; 
95%CI: -0.08, 0.32).  Haplotypes and diplotypes that included CYP1A1*3 and CYP1A1*4 
showed similar results.  Estimates for CYP1B1 and COMT alleles were close to the null.
Analyses of effect measure modification by age, body mass index, smoking status, alcohol use, 
oral contraceptive use, and number of fullterm births did not show deviations from additive or 
multiplicative expectations.  Our results reveal possible relationships between CYP1A1*3 and *4
polymorphisms and fibroid prevalence.  These results must be confirmed in other populations, 
and consider additional genes and variants within the estrogen metabolism pathway.  
vTo Taylor and Jasmine. When you grow up to be young women, I hope that this document will 
serve as proof that with faith and perseverance, you can attain absolutely anything.
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I. INTRODUCTION
A. Epidemiology of uterine leiomyoma
Uterine leiomyomas, commonly called uterine fibroids, are the most common reproductive 
tract neoplasm in women1. They are firm, benign tumors of smooth muscle origin2. They can 
occur singly or in multiples1, where multiple fibroids are clonally distinct from one another3,4. 
Fibroids can be detected by ultrasound when they are as small as 2-4 mm in diameter5, and have 
been documented to be as large as 72.39 cm in diameter1. They are classified into three groups:  
subserous, mural, and submucous1. Subserous tumors project out from the peritoneal surface of 
the uterus, mural tumors are within the uterine wall, and submucous tumors often project into the 
uterine cavity.  Some submucous or subserous fibroids are attached to the uterus by stalks 
(pedunculated fibroids) and, although infrequent, the submucous fibroids may protrude through 
the cervix and into the vagina1. 
Since the majority of tumors are asymptomatic, many remain undiagnosed5. Fibroids may be 
diagnosed during vaginal or abdominal examination, dilatation and curettage, hysteroscopy, 
laparoscopy, or transvaginal or abdominal ultrasound examination6,7. The most widely accepted 
non-invasive method of diagnosis is transvaginal ultrasound, which has an estimated sensitivity 
of 67-87% and specificity of 89-91%, using operative hysteroscopy and histological 
classification as the reference procedure6. Symptoms of fibroids include frequent urination, 
backache, constipation, abnormal bleeding, anemia, and pelvic/abdominal pain1,8-11. Severity of 
symptoms is generally associated with the number, size, and location of the tumors12.
2Treatment may include hormone therapy (anti-estrogen or anti- progesterone), observation, 
myomectomy (the removal of the fibroid), hysterectomy (the removal of the entire uterus), or 
embolization (the blockage of blood flow to the fibroid).1 Uterine leiomyomas are the leading 
indication for hysterectomies that occur in the United States, accounting for up to 40% of all 
hysterectomies13,14.  Choice of treatment is dependent on size of tumor, severity of symptoms, 
and rate of growth, as well as the woman’s desire to have children12.
Fibroids are common in reproductive age women1.  Studies have reported prevalences 
ranging from 3.3% to as high as 87%5,15-18.  Most cases are asymptomatic, yet symptomatic 
fibroids result in a significant amount of hospitalization19. Fibroids are more prevalent in African 
Americans than in Whites (16-87% among African Americans of reproductive age versus 9-78% 
among Whites of reproductive age)16,20,21.  Diagnosis rates are also higher among African 
American women (30.6 per 1000 woman years) when compared to White women (8.9 per 1000 
woman years) 18.  In addition, African American women are more likely to be diagnosed at 
earlier ages, report more severe symptoms, have a greater number of tumors, and have larger 
tumors than white women9. 
The etiology of fibroids remains poorly understood; however, several risk factors have been 
identified in epidemiologic studies. Factors affecting the hormonal milieu, such as pregnancy22-24, 
parity7,25, abortion25, low body mass index (BMI), 7,26and use of oral contraceptives22- 24,27 have 
been associated with a decreased risk of diagnosis.  However, studies have also reported positive 
associations with increased BMI22, abortions22, and oral contraceptive use21,23.  In addition to 
protection through the hormonal mileu, pregnancy may offer protection through apoptosis during 
post partum involution of the uterus28.  Smoking was inversely associated with fibroids in several 
studies21,23,29, but several other studies reported no association26. Other unconfirmed factors that 
have been associated with fibroids include hypertension, perineal talc use, history of pelvic 
inflammatory disease and chlamydial infection, and use of an intrauterine device22,24,30. 
3The etiology of fibroids is unclear; however, genetic mutations and epigenetic mechanisms 
are the fundamental basis for the development of tumors, benign or metastatic.  Evidence 
supports the role of clonal genetic abnormalities in the development of fibroid.  The following 
chromosomal abnormalities are common among fibroids:  translocation of (12;14)(q15;q23-24); 
deletion of (7)(q22q32); and rearrangements involving 6p21, 10q, trisomy 12.  Early studies were 
small; however, they were consistent in finding chromosomal aberrations in approximately 30-
50% of fibroids examined31-37.  One study, examining 90 tumors, found clonal abnormalities in 
34%; 31another study examining 93 tumors found abnormalities in 50%. 32 The most common 
abnormality in both studies was del(7)(q21.2q31.2).  Rein et al. (n=13) and Vanni et al. (n=40), 
found abnormalities in 54 and 32.5% of their samples (respectively), the majority of which 
involved the 12q14-15 and the 14q23-24 regions36.  A later larger study examining 182 tumors, 
found abnormalities in 29%. 37Chromosomal aberrations are tumor specific; their absence in 
normal uterine tissue suggests that they are nonrandom.  
Research by Pandis et al. showed that cytogenetically abnormal leiomyomas (those with 
detectable chromosomal abnormalities) had a higher mitotic index than those that were 
cytogenetically normal38, suggesting these abnormalities promote growth. A later study by Rein 
et al., examining 115 tumors, showed a relationship between chromosomal abnormalities and 
fibroid size; larger tumors were more likely to possess the t(12;14) abnormality, smaller tumors 
tended to possess the del(7), and middle sized tumors possessed a mosaic karyotype (composed 
of cells with and without abnormalities). 39 Consistent with these findings, another study 
examined 155 tumors and found those with translocations affecting 12q14-15 (but not deletions 
on chromosome 7) were significantly larger (8.9 + 5.1 versus 3.4 + 2.1 cm, p<0.001) than tumors 
with a normal karyotype (no chromosomal abnormalities)40. Translocations at the 12q14-15 may 
be associated with rearrangements of the high mobility group protein gene (HMGI) family; 
aberrations in the HMGI gene family have been found in various benign mesenchymal tumors 
4(e.g. pulmonary chondroid hamartomas, endometrial polyps, breast hamartomas, and lipomas) in 
addition to fibroid41-43.  This gene is often truncated and joined to ectopic DNA sequences, 
leading to fusion genes that result in increased expression44.  This suggests that HMGI may be a 
critical gene in the pathogeneisis of fibroid tumors.  HMGI aberrations may even be related to the 
location of fiborids.  Bronsens et al. examined 182 fibroids and found that intramural and 
subserous tumors had more chromosomal abnormalities (35% and 23% respectively) than 
submucous tumors (12%)37.
B. Uterine leiomyoma and hormones
Known risk factors for fibroid tend to parallel those of other hormonally induced tumors, 
such as endometrial cancer.  Although inconsistent, risk factors (e.g. BMI, oral contraception use, 
and parity as described in the section above) associated with the presence of fibroids support the 
influence of hormones on their development.  Clinical observations lend further support; for 
example, fibroids are only diagnosed after menarche45. After menopause, they diminish in size 
and/or disappear1,17.  
Studies have found molecular evidence that fibroids are progesterone related.  The addition 
of progesterone to cultured leiomyoma cells increased expression of an apoptosis inhibition 
protein (BCL-2) relative to control cultures46.  Brandon et al. demonstrated increased expression 
of progesterone receptor mRNA and protein in 29 leiomyoma compared to adjacent 
myometrium47.  
Evidence also suggests fibroids are estrogen related.  Andersen et al. found that they were 
hypersensitive to estrogen compared to normal myometrium, and that estrogen receptor levels in 
leiomyoma tissue were significantly elevated during the follicular phase48.  Another study of 8 
cases reported elevated expression of 4-hydroxyestradiol in fibroid tissue compared to normal 
5surrounding tissue49.   The effect (if any) of these hormones on fibroid development or natural 
history remains unclear.
C. Estrogen and Estrogen Metabolism
Estrogen is a steroid hormone chiefly produced by the ovaries prior to menopause; after 
menopause, estrogen is primarily produced in the peripheral tissues (mostly adipose) by the 
conversion of androstenedione to estrogen by aromatase.  A normal premenopausal adult female 
produces about 70 to 500 ug of estradiol per day, depending on the phase of the menstrual cycle.  
Regulation of biosynthesis and secretion is controlled by gonadotropins50.  Estrogens affect 
almost all systems in the body, including influence on bone formation and maintenance, as well 
as behavior and mood50.  In the uterus, estrogens increase cell progesterone receptors.  They also 
stimulate mucus production in the cervix, and mammary gland duct growth51. 
Endogenous estrogen exists in three main forms: estradiol, estrone, and estriol.  The most 
common circulating form is estradiol in premenopausal women, and estrone in postmenopausal 
women.  Estradiol can be converted to estrone, and visa versa. Either estradiol or estrone can be 
converted to estriol50. 
When estrogens circulate the body, they are primarily bound to sex hormone binding globulin 
and albumen.  It is believed that only unbound estrogens can enter target-tissue cells and induce 
biological activity50. Estrogen enters the cell through passive diffusion, then binds nuclear 
estrogen receptors (ER).  There are two forms of the estrogen receptor, ER and ER52.  The two 
forms differ in tissue distribution, binding affinity, and biological function53.  The ratio of 
expression of the two receptor types determines the biological response to estrogen.  The ER is 
primarily an intranuclear binding protein54, but it can shuttle between the nucleus and 
cytoplasmic compartments55.  Once estrogen binds to the ER, the ER changes its conformation, 
which allows it to activate the transcription of estrogen-responsive genes50.  Overall, estrogen 
6receptor levels are higher in leiomyomata tissue than in homologous myometrium56,57.  
Radioimmunoassays and immunocytochemical assays show a higher ER content in the 
subendometrial region than in the midmyometrial or the subserosal regions of the uterus58.  
The biologic effect of estrogen depends, in part, on how it is metabolized.  Metabolism of 
estrogen primarily occurs in the liver through two phases, but can also occur locally in other 
tissues.  Phase I metabolism creates an active site, primarily via hydroxylation, while Phase II 
conjugation reactions (methylation, glucuronidation, and sulfation) produce estrogen metabolites 
that may be excreted through the urine and feces, or be maintained in circulation.  This process is 
not always linear; Phase II metabolites can be de-conjugated back to an active intermediate.  
Phase I hydroxylation of estradiol (E2) and estrone (E1) mainly takes place at the 2 carbon (C-
2) position or at the 16 carbon (C-16) position, and is catalyzed by cytochrome P450 (CYP) 
enzymes.  More specifically, hydroxylation at the C-2 position is catalyzed primarily by CYP1A1 
and CYP1A2 enzymes, and hydroxylation at the C-16 position is catalyzed primarily by 
CYP3A4.   Hydroxylation at the C-2 position yields the catechol estrogens, 2-hydroxyestrone 
and 2-hydroxyestradiol (2-OH); likewise, hydroxylation at the C-16 position yields 16-
hydroxyestrone and 16-hydroxyestradiol (16-OH).  A smaller amount of hydroxylation occurs 
at the 4 carbon (C-4) position, catalyzed primarily by CYP1B1 and CYP3A4, which yields the 
catechol estrogens, 4-hydroxyestrone and 4-hydroxyestradiol (4-OH).  The 16-OH and 4-OH 
metabolites are more estrogenic than 2-OH59,60. 
Catechol estrogens are easily oxidized to highly reactive semi-quinones and quinones that 
generate reactive oxygen species through redox cycling, which may damage DNA and promote 
carcinogenesis.  Phase II methylation of 2-OH and 4-OH metabolites to less reactive metabolites 
(2-methoxyestrone and 2-methoxyestradiol and 4-methoxyestrone and 4-methoxyestradiol, 
respectively) reduces quinone formation.  This process is catalyzed by the catechol-O-
methyltransferase (COMT) enzyme.  During glucuronidation, another element of Phase II 
7metabolism, UDP-glucuronosyltransferases (UGTs) conjugate glucuronic acid with the estrogen 
to aid in deactivation.  Finally, sulfation (catalyzed by members of a superfamily of cytosolic 
sulfotransferase (SULT) enzymes) yields estrone sulfate or estradiol sulfate—water soluble 
conjugates that may be excreted in the urine.  Estrone sulfate is the most abundant form of 
estrogen in circulation.  
Figure A.1 presents a simplified version of the catechol estrogen metabolism process.  In 
summary, estrogen metabolism may lead to the formation of metabolites that vary with regard to 
their ability to stimulate estrogen receptors and/or damage DNA.  The net result of this process 
will depend in part on the activity of Cytochrome P-450 (CYP) and COMT enzymes that may 
favor different metabolic pathways.  Therefore, polymorphisms that influence the activity of 
these enzymes may influence estrogen-mediated tumorigenesis processes.  
D. Carcinogenic effects of estrogen
Animal studies have shown estrogen to be carcinogenic61.  For example, administration of 
estrogen to rodents increases the incidence of tumors of the mammary and pituitary glands, as 
well as the uterus, cervix, vagina, testicles, and bone62-65.  Although the majority of studies to 
date have looked primarily at breast cancer, there is adequate epidemiological evidence that 
estrogen is carcinogenic in humans66-69. Consequently, it has been listed as a carcinogen by the 
International Agency for Research on Cancer70.  Little to no research to date has examined the 
relationship between fibroid and estrogen regulating polymorphisms.
Estrogen promotes cell proliferation, which may increase the likelihood of spontaneous 
mutations caused by errors during DNA replication.  Once these mutations are present within the 
genome, continued replication would create clones of the mutations or perhaps more mutations.  
If these errors are uncorrected (either through repair or apoptosis) they can lead to a carcinogenic 
phenotype.   It appears that the metabolites of estrogen have specific and distinct activities in 
8estrogen-sensitive tissue.  The estrogen metabolite 4-OH was shown to be estrogenic in rats—
promoting uterine weight gain and mammary gland and bone proliferation71,72.  Conversely, 2-
OH metabolite had little to no estrogenic activity in these tissues71,72.  Another study found that 
2-OH metabolite was a weak estrogen agonist with respect to bone formation in rats73.  2-OH 
metabolite, however, had no estrogenic activity in human osteoblastic cells74.  Schneider and 
colleagues experimented with human breast cancer cells and found 2-OH metabolite to be 
antiestrogenic, suppressing cell growth and proliferation, but only in ER positive cell lines75.  It is 
important to note that activities of estrogen metabolites are due in part to the type of estrogen 
receptors present within a specific tissue53; the lack of a suitable receptor would mean less 
opportunity for estrogenic action. 
Estrogen metabolites may also be directly genotoxic.   Quantitatively, 4-OH is a less common 
metabolite than 16-OH and 2-OH; however it may be very critical to the genotoxic pathway.  4-
OH metabolite further metabolizes to 3,4-semi-quinone, which in turn is metabolized to 3,4-
quinone.  Quinones are recognized tumor initiators76.  Redox cycling between semi-quinones and 
quinones produces free radicals that may damage DNA.  In addition, the 3,4-quinone can form 
depurinating DNA adducts that increase the likelihood of DNA mutations76.  2-OH metabolite 
also metabolizes to 2,3-semi-quinone and later 2,3-quinone, which produces superoxide free 
radicals.  However, in contrast with 4-OH quinone metabolites, 2,3-quionone metabolites form 
stable DNA adducts that remain covalently bonded to DNA unless removed during repair.  
Overall, evidence suggests that the 4-OH catechol estrogen is both more estrogenic and more 
carcinogenic than 2-OH catechol estrogen72,77,78.  Rogan and collegues found four times the 
amount of 4-OH metabolite in the breast tissue of breast cancer cases than in controls.  Likewise, 
more 2-OH metabolite was found in breast tissue controls than cases91. 
Relevant polymorphic enzymes
9CYP1A1 and CYP1B1 are both key polymorphic enzymes in estrogen metabolism, triggering 
hydrocarbon hydroxylase activity.  COMT, another key polymorphic enzyme, is involved in O-
methylation.  They are expressed in a variety of tissues, including the liver, breast, lung, uterus, 
and kidneys. 79-84 Table A.1 details CYP1A1, CYP1B1, and COMT polymorphisms described 
below.  
CYP1A1
The CYP1A1 gene is located on chromosome 15, and is induced by polycyclic aromatic 
hydrocarbons.   At least seven polymorphisms have been identified85, but most do not appear to 
alter the function of CYP1A185.  
The polymorphism that was first detected (CYP1A1*2A, also known as m1) is a TC 
transition that creates a new MspI cleavage site located 1194 bp downstream of exon 7 in the 3’ 
non-coding region86.  One or more of this common allele have been found in up to 16% of 
healthy White and 44.1% of healthy African Americans87.  CYPA1A1*2A does not seem to alter 
the expression of CYP1A1; however, it is in linkage disequilibrium with the CYP1A1*2C (also 
known as m2) 88- 92polymorphism that may increase expression85.  The CYPA1A1*2C 
polymorphism is an AG transition located at nucleotide 4889 (exon 7), which results in an 
amino acid substitution of Isoleucine to Valine in the heme-binding region of the CYP1A1 
enzyme88.  One or more CYPA1A1*2C alleles were found in 7.4% of healthy Caucasians87,92, but 
no CYPA1A1*2C  alleles were found in healthy African Americans87.  This polymorphism has 
been associated with increased inducibility of CYP1A1, as measured by the ethoxyresorufin O-
deethylase (EROD) assay85. One animal study found that this mutation was not functionally 
important93.  The CYP1A1*3, allele, also known as m3, is in the 3’ non-coding region like 
CYP1A1*2A94.  This variant results from a TC transition.  It is unclear whether the CYP1A1*3 
allele affects function. This allele is common among African Americans (23.7%); 87several 
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studies did not find it in Caucasians87,92,94.  Another polymorphism, CYP1A1*4 (m4), is two bases 
upstream of the CYP1A1*2C site, also in the heme-binding region of CYP1A191.  The variant 
allele has a CA substitution located at the 4887 position of exon 7, resulting in a threonine to 
asparagine substitution.  This allele is found more frequently in Caucasians (~4%) than African 
Americans (~0.4%)87.
CYP1A1 has been examined in relation to a number of cancers.  Details on previous studies 
can be found in Table A.2. CYPA1A1*2A was associated with a greater risk of lung cancer in a 
study of 45 Japanese subjects95, but has not been associated with lung cancer among 
Caucasians81,90,96.  Drakoulis et al. reported an increased risk of lung cancer among those with the 
CYPA1A1*2C allele (OR=2.16; 95% CI 0.96-5.11, p=0.03).  Lung cancer was also not related to 
the CYP1A1*4 allele.  Cascorbi et al. reported its’ frequency in 576 lung cases and 304 controls 
was identical (case frequency = 2.87%, 95% CI = 1.32%-5.37%; control frequency = 2.87%, 
95% CI = 1.71%-4.47%)91.  The relationship of CYP1A1 alleles with breast cancer is conflicting 
as well. The CYPA1A1*2A variant was associated with breast cancer in a case-control study of 
932 women (>97% White), but only among women who initiated smoking before age 18 
(RR=5.65, 95% CI=1.11-11.7). 97 Another study found an independent association (OR=9.7, 95% 
CI=2.0-47.9) between the CYPA1A1*2A polymorphism and breast cancer among African 
American women (21 cases, 86 controls), but not Caucasian women (30 cases, 183 controls). 98
Other studies have not found a clear association of CYP1A1*2A with breast cancer87,99,100.  Some 
studies have found the CYPA1A1*2C variant to be independently associated with an increase in 
breast cancer risk80, while other studies have not87,101.  Still others have found a higher risk of 
breast cancer associated with this mutation only in the presence of environmental factors such as 
smoking80 or polychlorinated byphenols. 100 Bailey and colleagues found no association between 
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the CYP1A1*3 or CYP1A1*4 alleles and breast cancer in a case-control study (n=223 cases, 221 
controls). 87
CYP1B1
CYP1B1 is another enzyme key to the metabolism of estrogen.  The CYP1B1 gene was first 
identified by Sutter and colleagues and is located on chromosome 2 at the 2p21-22 region.  It 
contains three exons and two introns102.  CYP1B1 is expressed in a variety of tissues, including 
liver, lymphocytes, kidneys, testis, breast, colon, bladder, and uterus82-84. There are at least six 
single nucleotide polymorphic sites in this gene, four of which cause amino acid 
substitutions103,104.  
One CYP1B1 polymorphism, Ala119Ser, causes an amino acid change from alanine to serine 
at codon 119 in exon 2.  This polymorphism results from a G to T substitution.  Another 
polymorphism, Leu432Val, is located at codon 432 in exon 3.  Leu432Val is a G to C 
substitution, resulting in an amino acid change from leucine to valine.  The Ala119Ser variant is 
in complete linkage disequilibrium with another CYP1B1 variant, Arg48Gly.  Ala119Ser but 
does not alter enzyme function105.  Conversely, Leu432Val was shown to increase 2 and 4-
hydroxylation of estradiol by at least three-fold. 106Both of these SNPs are common, however the 
Leu432Val is more common among African Americans (~75%) than in Caucasians (43%)107,108.
In general, CYP1B1 expression is increased in human breast109,110, colon, lung, esophagus, 
skin, 110and uterine49 cancers relative to normal tissues. Watanabe and colleagues examined a 
Japanese population (n=990) and reported that Ala119Ser was associated with both breast (2 = 
8.32; d.f. = 2; p = 0.016) and lung cancers (2 = 7.02; d.f. = 2; p = 0.03). 111 Goodman and 
colleagues studied 129 ovarian cancer cases and 144 controls, and found an increased risk of 
ovarian cancer associated with the Leu432Val variant (OR=3.8; 95% CI = 1.2-11.4). 112 Thirty-
four percent of White prostate cancer cases studied by Tang et al. were homozygous for this 
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polymorphism, while only 12% of controls had this genotype107.  Another study (Fritsche et al.) 
examined 101 and 187 German cases and controls, respectively, and found an association with 
colorectal cancer (OR=1.93; 95% CI = 1.15-3.24). 113 Zheng et al. found a 2.3 fold elevated risk 
of breast cancer among women homozygous for the variant compared to women with the 
wildtype genotype.  Conversely, this variant was not associated with breast cancer in two larger 
case-control studies: De Vivo and colleagues’ analysis of data from the Nurses’ Health Study 
(n=909), 114and Watanabe and colleagues’ study of a Japanese population (2 = 0.43; d.f. = 2; p = 
0.808). 111
COMT
The catechol-O-methyltransferase (COMT) gene was first discovered by Axelrod and 
colleagues115.  Located on chromosome 22, it can exist in either a membrane bound form (M-
COMT) or a soluble form (S-COMT).  COMT catalyzes the transfer of a methyl group from S-
adenosylmethionine to catecholamines, inactivating biologically active catechols.  Like the CYP 
genes, COMT is expressed in a variety of tissues including brain, liver, kidney, uterus, and 
breast116.  
Val158Met is a common SNP in exon 4 of the COMT gene.  This polymorphism results from 
a G to A at codon 158 of M-COMT and codon 108 of S-COMT.  This substitution causes an 
amino acid change of valine to methionine.  The methionine protein has lower enzymatic activity 
than valine.  
The low activity variant genotype has been associated with breast cancer in a number of 
studies.  Huang et. al. observed a 4 fold increase in risk for breast cancer among women with two 
variant alleles compared to women with one or less allele (n=150 cases, 150 controls) 117.    
Thompson et. al. examined 570 women and found a 2 fold risk in premenopausal women with 
two variant alleles.  In postmenopausal women, however, there was an inverse relationship118.  
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Conversely, Lavigne et. al. found the exact opposite.  Premenopausal women with 2 variant 
alleles were inversely associated while postmenopausal women with 2 variant alleles had an 
increase risk119.  These contradictory findings suggest that the variation in effect of the COMT
Val158Met polymorphism may be due to factors beyond menopausal status.  For example, 
Mitrunen et. al. found an inverse association with breast cancer among postmenopausal women 
with 2 variant alleles and low body mass index120.  Mitrumen et. al. also found that 
postmenopausal women with this genotype and early age at menarche had an 8-fold increase in 
risk; postmenopausal women with this genotype and long term use of estrogen had a 4-fold 
increase in risk. This polymorphism has also been linked to neurological conditions such as 
Parkinson’s disease121 and attention deficit hyperactivity disorder122, as well as psychological 
conditions such as suicidal behavior123,124 and alcoholism125-127.   
Research suggests that estrogen and estrogen metabolites are carcinogenic and/or tumor 
promoters.  Polymorphisms that control the production of estrogen metabolites may influence the 
initiation and growth of fibroids, which would explain the evidence supporting estrogen’s link to 
fibroids.
E. Potential modifiers
Several risk factors for leiomyoma, specifically BMI, smoking, and alcohol use, may be 
associated with the tumors through their effects on estrogens.  
BMI
Obesity (BMI > 30 kg body weight/m2 height) is associated with altered hormone levels and 
ovarian function.  A small study following 20 obese women found that weight loss  improved 
menstrual cyclicity128.  One cross-sectional study by Dorgan et al. (N=107) showed that heavier 
women had significantly lower plasma sex-hormone binding globulin levels (percent 
difference/kg = 1.2; 95% CI 0.6-1.9). 129 A cross-sectional study by Boyapati et al. also found an 
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inverse association between BMI and sex hormone binding globulin130, which may result in a 
higher level of circulating free estrogens.  Likewise, this same study, along with a previous study 
by Sheinder et al. (N=22, pre-menopausal women), found estradiol and estrone levels to be 
positively correlated with body size130,131.  Similarly, a case-control study conducted by Bruning 
et al. (n=225 cases, 44 controls) demonstrated that BMI was positively correlated with serum 
estrogen levels in women aged 38-75 years132. In contrast, a prospective study by Westhoff et al. 
(N=175) did not find an association between body weight and estrogen levels, but did find an 
inverse association with progestin levels133.  
Studies have shown that BMI is associated with an increased risk of being diagnosed with 
fibroids.  A study of Finnish twins found that women with fibroids had a higher mean BMI (23.7 
vs. 21.7, p=0.009) than women without fibroids7.  A large prospective study of 94,095 
multiethnic women found a modest association between BMI and fibroids (RR for BMI > 30 
compared to BMI between 20.0-21.9  = 1.48, 95% CI 1.15 – 1.91)26.  Race did not appear to 
modify the association between BMI and fibroids.  In contrast to these studies, a hospital-based 
case-control study (n=275 cases, n=722 controls) of Italian women by Parazzini et al. did not find 
an association with fibroids and BMI.  
Smoking
Smoking has been implicated in a number of cancers, yet antiestrogenic effects may be 
protective in cancers that are estrogen dependent.  Animal studies have shown that a chief 
constituent of cigarette smoke, nicotine, increases the number of regressing follicles in the ovary 
and blocks the aromatase enzyme, inhibiting ovulation and estradiol production, both in vivo and 
in vitro134.  Likewise, human studies have found lower estrogen levels associated with cigarette 
smoking.  Westhoff et al. found cigarette smoking was associated with decreased estradiol levels 
during the midcycle and luteal-phase of the menstrual cycle133.   Another study examined 197 
infertile women and found a strong negative correlation between a metabolite of cigarette 
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smoking, cotinine, and estradiol levels (r=-0.65)135.  Predictably, smoking appeared to reduce the 
effectiveness of hormone replacement therapy.  Smokers on oral hormone replacement therapy 
had estrogen levels that were 40-70% lower than that of non-smokers136.  
Several studies have found smoking to be inversely associated with fibroids.  A small case-
control study by Cramer et al. showed a negative association between pathologically confirmed 
leiomyomas and amount of cigarettes smoked per day, with 22 controls averaging 11 cigarettes 
per day while 22 cases averaged 7 per day29.  A larger case-control study (n=535 cases, n=535 
controls) found that smokers of 20 cigarettes a day had approximately two thirds the risk of 
developing pathologically confirmed fibroids than nonsmokers23.  Faerstein et al. found an 
association between fibroids (pathologically or sonographically confirmed) and duration of 
smoking in their case-control study (n=318 cases, n=394 controls), with women who smoked 19 
or more years being less likely to be diagnosed with fibroids than women who never smoked 
(OR=0.6, 95% CI 0.4-1.1). 21 No association was found between smoking and fibroids in the 
Nurses’ Health Study II26, or the Black Women’s Health Sutdy137, which are both prospective 
studies.  Nonetheless, on balance, epidemiologic and biologic data suggest that smoking may be 
protective against fibroids through its antiestrogenic effects. 
Alcohol Use
Alcohol consumption is associated with increased levels of endogenous estrogen.  Results 
from the Nurses Health Study indicated that alcohol use was positively associated with estrone 
sulfate concentrations138.  A cross-sectional study by Onland-Moret showed that Dutch women 
who consumed more than 25g of alcohol per day had higher levels of estrone and estradiol than 
nondrinkers139.  A clinical trial conducted by Reichman and colleagues show that women who 
consumed 30g of alcohol per day had higher total estrogen concentrations than nondrinkers140.  
Conflicting results have also been presented by studies with smaller population sizes and inferior 
study designs.  A study by Cauley et al. examining 176 Caucasian women found estrogen levels 
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to decline with increasing alcohol consumption141.  London and colleagues found no association 
between alcohol intake and estrogen levels in their study of 325 healthy pre-menopausal 
women142, and Dorgan’s cross-sectional study (N=107) showed no association either143.  
Alcohol use has been implicated as a modifiable risk factor for several cancers.  Several large 
population based studies have also found an association between alcohol use and fibroids.  The 
Nurses’ Health Study found an association between fibroids and current alcohol consumption 
among pre-menopausal women18.  Wise et al. studied participants from the Black Women’s 
Health Study and found a positive association between fibroids and alcohol use, particularly 
beer137.  Alcohol’s potential relationship with estrogen may explain its positive association with 
fibroids. 
F. Significance
Fibroids are the most common reproductive tract neoplasm in all women (up to 87%), and 
they substantially affect higher proportions of African American women for more of their 
reproductive lifetime compared to White women.  Although this smooth muscle tumor is benign, 
it is associated with significant morbidity and is the leading cause for hysterectomy (> 200,000 a 
year) in the United States.  Fibroids also cause dysmenorrhea, menorrhagia, and possibly 
infertility.  The causes of fibroids are unknown; however, uterine fibroids are influenced by the 
presence or absence of hormones, notably estrogen.  Uterine fibroids are primarily diagnosed 
during the reproductive years--after menarche and before menopause.  Estrogen metabolism may 
influence fibroid development by influencing exposure to estrogen and metabolites with 
estrogenic activity, and/or by affecting the formation of reactive catechol estrogens that may 
directly or indirectly induce DNA damage. 
All women are exposed to estrogen and therefore catechol estrogen.  If more metabolites are 
being created than can be conjugated, then metabolites have the potential of causing both 
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estrogenic effects and genotoxic damage.  Polymorphisms of estrogen metabolism genes may 
affect how estrogen is metabolized, which consequently may determine which predominant 
conjugates are created.  Polymorphisms in genes that encode three of these enzymes, CYP1A1,
CYP1B1, and COMT may influence the rate of estrogen metabolism and the proportion of 
estrogenic and reactive metabolic byproducts formed locally in uterine smooth muscle.   These 
differences in estrogen metabolism could partly account for differences in risk of fibroid 
development. 
Since the etiology of fibroids is unknown, discovering genetic variants associated with the 
disease would add to our understanding of its pathogenesis and could potentially lead to new 
tailored medical treatments.  The absence of an association with CYP1A1, CYP1B1, and COMT
polymorphisms would not rule out the importance of estrogen metabolism genes in the 
development of fibroids, since the polymorphisms examined in this study represent only a small 
sample of the gene variants in this pathway.  There are also additional variants which may be 
more informative.  More studies will need to be conducted, considering a much broader range of 
variants in these genes and other genes in the same pathway before any conclusions can be made.
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II. STATEMENT OF SPECIFIC AIMS
A. Study questions
The aim of this dissertation is to examine the relations between uterine leiomyomata
(fibroids) and estrogen metabolism gene polymorphisms that may influence estrogen activity and 
catechol estrogen formation. Our first hypothesis is that women with one or more variant alleles 
will be more likely to have uterine fibroids, and their tumors will be larger.  We also hope to 
better understand ethnic differences (African American versus White) in the prevalence of 
uterine fibroids by examining associations between estrogen metabolism gene polymorphisms 
and uterine fibroids within ethnic strata.  We hypothesize ethnic differences in the prevalence of 
polymorphisms may explain some of the ethnic differences in the prevalence of uterine fibroids 
between African Americans and Whites.  As a secondary aim, we propose to evaluate the 
relationship between gene-environment interactions and uterine fibroids.  The hypothesis is that 
women with one or more variant alleles and selected environmental factors will be more likely to 
have uterine fibroids than women without a variant allele and environmental factor.  
B. Specific Aims
Primary Aims are as follows: 
1. To determine if there is a positive association between the presence or size of uterine 
fibroids and one or more of the following polymorphisms for CYP1A1:  *2A, *2C, *3, *4.
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2. To determine if there is a positive association between the presence or size uterine 
fibroids and one or both of the following polymorphisms for CYP1B1:  Ala119Ser and 
Leu432Val.
3. To evaluate whether associations with the CYP1A1 and CYP1B1 variants noted above are 
modified by race. 
4. To infer haplotypes for CYP1A1 and CYP1B1 and evaluate whether the least common 
inferred haplotypes are positively associated with the presence or size of uterine fibroids.
5. To determine whether there is a positive association between the Val158Met 
polymorphism of COMT and uterine fibroids.
Exploratory Aim:
1.  To evaluate whether associations with the CYP1A1 and CYP1B1 variants noted above 
are modified by smoking status, age, alcohol use, or BMI.   
III. METHODS
A. Overview of methods
The present study is based upon the National Institute of Environmental Health Sciences 
(NIEHS) Uterine Fibroid Study, a cross-sectional study of urban women aged 35-49 (Donna 
Baird, PI).  Our primary aim is to determine whether polymorphisms of CYP1A1, CYP1B1, and
COMT are associated with the prevalence of uterine leiomyomas in a sample population of 
African American and White women from a prepaid urban health plan.  Standard analysis 
techniques will be conducted to determine prevalence risk ratios.    
B. Study Population
The data used for this study are from the National Institute of Environmental Health Sciences 
Uterine Fibroid Study (UFS), in collaboration with the George Washington University Medical 
Center.  The UFS was designed to determine the prevalence of leiomyoma in African American 
and White women1.  Participants in the parent study were randomly sampled from female 
members of a prepaid urban health plan with approximately 50% black membership and a broad 
socioeconomic base.   To be eligible for the parent study, participants had to be female, aged 35-
49 years, English speaking, and a member of the health plan’s Washington, DC site.  This age 
range was chosen because it precedes natural menopause for the majority of the women, and 
would capture women with the highest prevalence of uterine fibroids.  In addition, ultrasound 
screening for fibroids is more sensitive among women in this age range, since fibroids may 
regress in size after menopause and are therefore more difficult to detect.  
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Women included in the sample (N=2,384) were sent a letter that described the study, and 
were later telephoned to confirm eligibility and obtain informed consent.  Of the 2,384 women 
that were randomly sampled, 129 (5%) could not be contacted, 150 (6%) declined screening for 
eligibility, and three (0.1%) were not contacted because of screener error.  Of the 2,102 women 
screened, 316 (16%) were ineligible, mostly because they were no longer receiving care at the 
Washington, DC site.  Nineteen percent of eligible women (N = 335) declined participation.  In 
addition, four women who were unsure about participating and 17 women who agreed to 
participate could not be recontacted for the telephone interview.  In total, 80% of eligible women 
(N=1,430) participated in the parent study.
The present study only included women from the parent study who were premenopausal and 
had DNA available for genotyping.  Of the 1,430 women in the parent study, 1,245 (87%) were 
premenopausal, and 1,064 of these had DNA available for genotyping. The majority of the final 
sample was African American (n=583), followed by White (n=404).  The number of women who 
were neither African American nor White was small (n=77) and therefore not included in the 
analysis sample. 
Preliminary Data
Table A.3 shows the distribution of exposure and outcome characteristics of the study 
population by race.  There were 404 White women, 583 African American women, and 77 
women of other races.  Fibroids were detected disproportionately in African American women 
(73%), compared with 51% of White and 57% of women classified as ‘other’ race.  The majority 
of women with ultrasound detectable fibroids had fibroids that were between 2-4 cm in diameter.  
Only one quarter of African American women had a BMI in the normal range(<25).  The other 
75% were overweight or obese (BMI=25-29.9 and BMI >30, respectively).  Approximately half 
of White women and women of other races had normal BMIs.  The age distribution of study 
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participants was similar across races, with approximately one third aged 35-39, 40-44, and 45 and
older, respectively.  African American participants were more likely to be current smokers (29%) 
than White participants (8%) or participants of other races (16%).   The majority of women had a 
history of oral contraceptive use (92% of African American, 83% of White, and 78% of women 
of other races).  
Approximately 60% of African American and White women and 50% of ‘other race’ women 
were homozygous wildtype for CYP1A1*2A.  Only 4% (n=23) of African Americans and 2% 
(n=9) of Whites were homozygous variant (C/C) for CYP1A1*2A, compared with 16% (n=12) of 
women of other races.  
The overwhelming majority of African American and White women were homozygous 
wildtype for CYP1A1*2C (98% and 90% respectively), compared with 67% of women of other 
races.  Only one white woman and no African American women were homozygous variant (G/G) 
for CYP1A1*2C, in contrast with 9% (n=7) of women of other races. 
Previous studies have found the variant CYP1A1*3 allele (C/C) primarily in African 
Americans2-4.  Our population is similar.  Approximately 86% of African American participants 
were homozygous wildtype, 14% were heterozygous, and <1% (n=4) were homozygous variant 
for CYP1A1*3. In contrast, over 99% of White participants and 95% of other race participants 
were homozygous wildtype for CYP1A1*3.  
The prevalence of CYP1A1*4 was similar across racial categories.  Over 90% of participants 
within each race possessed the wildtype genotype, and only one ‘other race’ participant was 
homozygous for the CYP1A1*4 variant. 
About one quarter of African American participants were homozygous wildtype for the 
CYP1B1 Ala119Ser polymorphism, while 50% were heterozygous. In contrast, about half of 
White and ‘other race’ participants were homozygous wildtype for Ala119Ser, and only a third 
was heterozygous.
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Half of African American participants were homozygous wildtype for the CYP1B1
Leu432Val polymorphism.  The other half possessed one or more of the variant alleles (37% 
heterozygous, 7% homozygous variant).  Only 17% of White participants had the homozygous 
wildtype genotype, while the majority had one or more variant alleles (51% heterozygous, 33% 
homozygous variant).  Likewise, the majority of participants of other races had one or more 
variant alleles (25.97% wildtype, 40.26% heterozygous, 33.77% homozygous variant).      
Almost half of the African American participants possessed the homozygous wildtype 
genotype for the COMT Val158Met polymorphism.  Forty-three percent were heterozygous and 
9.62% were homozygous recessive.  Approximately one quarter of White participants were 
homozygous wildtype for this polymorphism.  Half of the White participants possessed the 
heterozygous genotype, while the quarter possessed the homozygous variant genotype.
The distributions of all of the CYP1A1, CYP1B1, and COMT genotypes to be analyzed in the 
proposed study were evaluated for consistency with Hardy Weinberg equilibrium (HWE).  HWE 
was calculated using the following formula:  
(p + q)2 = p2 + 2pq + q2, 
where p equals the proportion of one of the alleles, and q equals the proportion of the other allele.  
The above equation gives the expected genotypic frequencies of p2, 2pq, and q2, and a chi-square 
test was used to determine whether the difference between observed and expected genotypic 
frequencies was statistically significant. HWE was calculated among controls.  It was also 
evaluated among the racial groups separately (White, African American), since allele frequencies 
varied by race.  The distribution of all genotypes within racial groups, were consistent with HWE 
(df=1, p=0.05, critical value=3.84).  Table A.4 shows the expected and observed frequencies of 
each genotype, and chi-square results.
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C. Data Collection and Classification
Overview
Demographic data for the current study were collected by a self-administered questionnaire, 
and by a telephone interview (for reproductive and gynecologic history data) conducted by 
trained staff. Ultrasound examinations (to detect uterine leiomyomas and determine their size), 
blood collection (for DNA) and weight measurements were performed during a clinic visit1. 
DNA was genotyped using matix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS), an accurate and efficient technique that permits simultaneous 
identification of multiple single nucleotide polymorphisms (SNPs) in a single reaction5.       
Outcome Assessment
Transabdominal and transvaginal ultrasounds to detect uterine fibroids were performed on 
premenopausal participants by sonographers who were certified by the American Registry of 
Diagnostic Medical Sonographers, under the supervision of a radiologist trained in 
ultrasonography1.  If a premenopausal woman had a pelvic ultrasound examination recently, the 
radiology records from that examination were used to assess fibroid status. Women were 
classified as positive for uterine leiomyoma if the ultrasound examination associated with the 
clinic visit identified fibroids; they were classified as negative if the sonogram evidence 
confirmed the absence of fibroids.  The ultrasound examination was also used to determine the 
size of the largest fibroid.  Fibroid size was categorized into four levels:  no detectable fibroids, 
largest fibroid 2 cm or less in diameter (small), largest fibroid 2-4 cm in diameter (medium), and 
largest fibroid 4 cm or larger in diameter (large).  
Genotype Assessment         
Fasting blood samples were collected during the clinic visit. After preparation (aliquotion 
and centrifugation), blood samples were sent to an outside laboratory (BioServe Biotechnologies, 
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Ltd.) for DNA extraction and genotyping.  DNA was extracted from whole blood using a 
modified salt precipitation DNA extraction kit, GenQuick (manufactured by BioServe 
Biotechnologies).  Polymorphisms of CYP1A1, CYP1B1, and COMT were identified using 
matrix-assisted laser desorption/ionization time-of-flight mass spectometry (MALDI-TOF MS) 
technique. 
The MALDI-TOF system is a high throughput, cost-effective, and accurate technique that 
simultaneously performs multiple genotyping analysis on very small quantities of DNA5.  The 
process begins with polymerase chain reaction (PCR) amplification of a 60 to 200 base pair 
region surrounding the SNP of interest.  The corresponding MassEXTEND primer extension 
reaction generates allele-specific products that are applied to a SpectroChip array.  The 
SpectroChip is placed in the MALDI-TOF spectrometer where a laser beam causes desorption 
and ionization.  The product then travels towards a detector.  The time that it takes for the 
product to reach the detector determines the product’s unique mass.  SpectroTYPER software 
was used to analyze the results.  Assays failed for less than 2% of all participants for each SNP.  
To ascertain genotying error from genotyping, repeat samples were run for 30 participants. All 
but one of the repeat sample pairs were in agreement with one another.  The exception was 
discordant for Val158Met of the COMT gene.
The SNPs (CYP1A1*2A, CYP1A1*2C, CYP1A1*3, CYP1A1*4, Ala119Ser, Leu432Val, 
and Val158Met) were chosen based on their associations with estrogen mediated tumors in 
previous research.  The primers used for each SNP are listed in Table A.5. For each SNP, 
participants were classified as homozygous wildtype if they had two copies of the wildtype allele 
(referent group), homozygous variant if they had two copies of the variant allele, and 
heterozygous if they had one wildtype allele and one variant allele. Table A.3 details the 
prevalence of each SNP in the study population.  
Covariates
39
A self-administered questionnaire was used to collect demographic data.  Telephone 
interviews were used to gather reproductive and gynecologic history data.  Weight was measured 
during a clinic visit.  
Body Mass Index (BMI).  BMI (kg/m2) was determined based on weight recorded at the clinic 
visit by a trained researcher.  Height was self-reported during the telephone interview. Previous 
Participants were then categorized as follows:  normal (BMI below 25), overweight (BMI 
between 25 and 29.9), and obese (BMI = 30 or above).  
Age.  Age at enrollment (in years) was self-reported during the telephone interview.  Age was 
categorized into five-year intervals:  35 – 39, 40 – 44, and 45 and above.
Smoking Status.  During the telephone interview, participants were asked, “Have you ever 
smoked an average of at least one cigarette a day for six months or more?”  Women who 
responded “no” were classified as non-smokers.  Women who responded positively were asked 
additional questions to determine their current smoking status.  Women were classified as former 
smokers if they answered negatively to the question, “Do you currently smoke even one cigarette 
per day?”  Positive responders were classified as current smokers.  
Race.  Race and ethnicity were self-reported in the mailed questionnaire.  Specifically, 
participants were asked, “Which category best describes you” and given the following options:  
“White/not Hispanic,” “White/Hispanic,” “Black/not Hispanic,” “Black/Hispanic,” 
“Asian/Pacific Islander,” and “American Indian/Eskimo/Aleut.”  Respondents were also given 
the option of specifying other categories.  If participants did not respond to the question on 
race/ethnicity in the mailed questionnaire, they were asked again during any subsequent 
telephone interview. Clinic records were used to determine race if it was not available from the 
mailed questionnaire or interview. 
Participants were classified as African American if they self-identified themselves as “Black” 
in any way (e.g. Black/not Hispanic, Black and White, etc.).  Participants were coded as 
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Caucasian if they self-identified themselves as “White” in any way, with the exception of 
“White” in combination with “Black.”  Only 77 of the 1,064 women included in the present study 
were classified as a race other than “Black” or “White.”  Therefore, these women were grouped 
together in an “other race” category.
Births after age 24.  During the telephone interview, participants were asked, “Have you given 
birth to any children?” and “In what month and year?” The age of the mother at the time of birth 
was calculated based on her response and her birthday.  Only deliveries occurring after the age of 
24 were considered for the control of a parity effect.  The protective effects were not seen for 
births at early ages in previous research28.
Oral contraceptive use.  Oral contraceptive use was recorded during the telephone interview.  
Participants were asked, “Have you ever used birth control pills?”  A favorable response was 
categorized as positive for oral contraceptive use.   
Alcohol use.  Alcohol use was self-reported in the mailed questionnaire.  Participants were asked 
how often they consume beer, wine, and liquor as separate questions.  They were given the 
following options:  never or less than 1 per month, 1-3 per month, 1 per week, 2-4 per week, 5-6 
per week, 1 per day, 2-3 per day, 4-5 per day, and 6+ per day.  Next, they were asked how much 
they consumed (small, medium, or large serving size).  As a reference, a medium size serving for 
beer, wine, and liquor was defined as a 12 ounce can or bottle, one medium glass, and one shot, 
respectively.  
D. Analysis
Power Calculations 
Power was calculated using the Power Program V3.06.  Calculations are based on the known 
prevalence of dichotomous genotypes (homozygous wildtype versus heterozygous and 
homozygous variant genotypes, grouped together) and uterine fibroids (73% and 51% among 
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African American women and White women, respectively) in the study population.  
Heterozygous and homozygous variant genotypes were grouped together to increase power.  
Power calculations are based on estimation of odds ratios instead of prevalence risk ratios; 
however the estimations should be roughly comparable.  Tables A.6 and A.7 show the estimated 
power to detect statistically significant odds ratios of 1.5, 2.0, and 3.0 (where =.05) given the 
distribution of genotypes and fibroids among White and African American participants, 
respectively. There is adequate power to detect an OR of 3.0 in both groups for the following 
SNPs:  CYP1A1*2A, Ala119Ser, and Leu432Val.  However, there may not be enough power to 
detect a OR of 3.0 for CYP1A1*2C and CYP1A1*4 for African Americans.  Within the White 
group, there may not be enough power to detect a OR of 3.0 for CYP1A1*3. 
Haplotyping
PHASE version 2.0.27,8 was used to statistically estimate the frequencies of various haplotype 
phases, using the Markov chain-Monte Carlo algorithm, given the distribution in the study 
population.  A haplotype is a group of alleles on the same chromosome that tend to segregate 
together.  The identification of a haplotype identifies all other polymorphic sites at a region, 
though the proposed study is limited in accomplishing this due to the small number of SNPs.  To 
account for uncertainty, we limited the sample to include only those with data for 3 of 4 CYP1A1
polymorphisms.  For the CYP1B1 haplotype analysis, we included those with data for both 
polymorphisms.  To further account for uncertainty, the haplotype probability estimates < 0.90 
were excluded.  Haplotypes were modeled with the most common haplotype as the referent.  
Since haplotype analysis was not the focus of the parent study, SNPs were not chosen to capture 
all of the variability of the gene.  Unlike typical haplotype analyses, haplotype reconstruction 
were done with sparse coverage for this study.
Main effects of genotypes
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When stratified by race, all genotypes were consistent with HWE.  Each polymorphism and 
haplotype was analyzed singly (wildtype versus homozygous variant and heterozygous variant 
grouped together) to determine whether there is an association with the presence of fibroids.  The 
main effects of the genotypes was determined using the following model for the dichotomous 
outcome of fibroid presence:  
Log [p(fibroids)] = 0 + 1(polymorphism/haplotype).
For the polytmous outcome of fibroid size, the following models was used with “no fibroids” as 
the common reference:
log[p(fibroids<2cm)] = 0 + 1(polymorphism/haplotype)/1+0 +   
1(polymorphism/haplotype),
log[p(fibroids 2-3.999cm)] = 0 + 1(polymorphism/haplotype)/1 + 0 + 
1(polymorphism/haplotype),  and
log[p(fibroids >4cm)] = 0 + 1(polymorphism/haplotype)/1 + 0 + 
1(polymorphism/haplotype).
All parameter estimates were obtained using SAS 8.0 (Statistical Analytic Systems, Version 8.0; 
SAS Institute, Inc., Cary, NC; 1999).   The exponentiated parameter estimates represent 
prevalence risk ratios and is interpreted as the risk of having fibroids among those with the 
variant polymorphism (e.g. homozygous and heterozygous variant for CYP1A1*2A) or haplotype 
versus the risk among those with the wildtype polymorphism (e.g. homozygous wildtype for 
CYP1A1*2A).   These models were analyzed again with fibroid size as the outcome.  
Based on previous literature described earlier (Chapter 1), all genotype main effects were 
examined for effect modification/interaction by alcohol use (<0.5, 0.5-<3, 3-<7, and 7 or more 
drinks per week) BMI (<25, 25-29.99, and >30), smoking (never smoker, current smoker, and 
past smoker), oral contraception use (never used, current/past use), number of births after age 24
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(none, 1, 2, 3 or more), and age (35-39, 40-44, >=45).  Effect measure modification was assessed 
on the multiplicative and additive scales by evaluating joint and independent effects of each 
polymorphism and the potential effect modifier relative to a common referent group.  An 
example such a model for the joint effects of BMI and a gene variant relative to a common 
referent exposure group (wildtype polymorphism and BMI <25) is as follows:  
log [p(fibroids)] = 0 + 1(var) + 2(BMI <25) + 3(BMI 25-29.99) + 
4(BMI>30) + 5(BMI<25*var) + 6 (BMI 25-29.99 * var) + 7
(BMI>30* var),
where wt = wildtype polymorphism (two wildtype alleles) and var = variant polymorphism 
(either homozygous variant or heterozygous variant).  Models assessing effect modification by 
smoking and alcohol use were similar.  For multiplicative interaction, a likelihood ratio test 
determined the goodness of fit of the model with main effects terms only (for example, BMI 25-
35, BMI >35, and the polymorphism), and the magnitude of risk (prevalence) ratio modification 
were assessed by comparing observed joint effect estimates with expected values assuming 
multiplicative risks.  Interaction on the additive scale (prevalence difference modification) were 
evaluated by comparing observed versus expected joint effects of the polymorphism with BMI, 
smoking status, and alcohol assuming additive risks.  In addition, Interaction Contrast Ratios and 
95% CI were calculated to estimate departures from additive risks.  
A priori assessments using a Directed Acyclic Graph revealed race as a potential confounder.  
Race is related to uterine leiomyoma, which occur more frequently in African Americans than in 
other races1,9-12. Race is also related to the genetic polymorphism CYP1A1*3, which is more 
prevalent in African Americans than in other races4.  Population stratification may cause other 
factors to confound the relationship between the polymorphisms and uterine leiomyoma.  
Smoking, BMI, oral contraceptive use, and parity may be related to uterine fibroids; they are 
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related to the genetic polymorphism CYP1A1*3, via race.  Since all analyses will be stratified by 
race, it is less likely that population stratification would pose a bias.  In order to pose a bias, there 
would have to be subgroups that differ from other subgroups with regard to genotype and fibroid 
prevalence within the same racial category.  All factors were included in the model (by race) one 
at a time.  A factor is considered a confounder if it’s inclusion into the model produces a change 
in effect >10%. 
Prevalence risk estimates for CYP1A1*3 will were estimated only for the African American 
strata due to the small numbers of African Americans with these alleles.  The precision of all 
estimates would be limited by small numbers in the other races category; consequently, we did 
not conduct analyses separately for this group.
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IV. RESULTS
A. Val153Met Polymorphism of Catechol-O-Methyltransferase and Prevalence of Uterine 
Leiomyomata
1. Abstract
The catechol-O-methyltransferase (COMT) gene encodes enzymes that inactivate catechol 
estrogens and may have a protective role in estrogen induced tumorigenesis, such as uterine 
leiomyomata (fibroids).  Val158Met is a common single nucleotide polymorphism (SNP) of the 
COMT gene (Ex4-12 G>A; rs4680) that results in a lower activity enzyme, possibly increasing 
susceptibility to tumorigenesis.  However, a recent study reported an association between the 
high activity allele and fibroids.  The purpose of this study was to evaluate the relation between 
the COMT Val158Met polymorphism and uterine fibroids.  The data are from the National 
Institute of Environmental Health Science Uterine Fibroid Study, including 583 African 
American and 404 White women with genotype and ultrasound screening data for assessment of 
fibroid status.  Log regression models were used to estimate prevalence ratios for fibroids 
prevalence.  In addition, main effects were evaluated for effect measure modification by alcohol 
use, BMI, smoking, births after age 24, oral contraceptive use, and age.  No associations between 
fibroids and Val158Met were observed for either ethnic group.  This study suggests variation in 
this polymorphism alone does not affect fibroid prevalence.  
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2. Introduction
The catechol-O-methyltransferase (COMT) inactivates catechol estrogens by catalyzing 
the transfer of a methyl group from S-adenosylmethionine to catecholamines. A by-product of 
COMT, 2-methoxyestradiol, may have a protective role in estrogen induced tumorigenesis by 
inhibiting angiogenesis1 and cell-proliferation2-4.  Val158Met (Ex4-12 G>A; rs4680) is a 
common polymorphism that may result in a lower activity enzyme5.  The low-activity Met allele 
has been positively associated with breast cancer in some, but not all studies6-8.  The present 
study evaluated the relation between COMT Val158Met and uterine fibroids, which are common 
benign estrogen-responsive tumors in premenopausal women that were positively associated with 
the Val/Val genotype in a recent study 9.
3. Methods
Study Population
Data are from premenopausal participants in the National Institute of Environmental 
Health Sciences Uterine Fibroid Study (UFS).  Participants were women randomly selected from
a prepaid urban health plan between 35-49 years of age.  Detailed information about the UFS is 
published elsewhere10.  Women included in this analysis had available DNA and self-reported 
their race as African American or White (N=987).
Demographic and medical history data were obtained via telephone interview (including 
oral contraceptive use, smoking, height, and full-term births after age 24 which were associated 
with fibroids in previous analysis of this study population11) and a self-administered 
questionnaire (which included race, alcohol use.)      
Outcome Assessment
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Fibroid status was ascertained by screening with transabdominal and transvaginal 
ultrasound examinations (performed under the supervision of a radiologist by sonographers 
certified by the American Registry of Diagnostic Medical Sonographers) or was derived from 
clinical radiology records for women with a recent pelvic ultrasound exam at the study clinic.  
The presence or absence of fibroids and the diameter of the largest fibroid were determined for 
each participant.  
Genotype Assessment
DNA was extracted from whole blood samples using a modified salt precipitation DNA 
extraction kit (GeneQuick).  The Val158Met polymorphism was identified using matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF)12.  
Statistical Analysis
Binomial log regression models were used to estimate race-specific prevalence ratios for 
any fibroids versus no fibroids, or for small (<2cm), medium (2-<4), or large (>4cm) fibroids 
versus no fibroids (Statistical Analytic Systems, Version 8.0; SAS Institute, Inc., Cary, NC; 
1999)13,14.  Confounding was identified based on >10% change in prevalence ratios for COMT
when potential confounders (age, body mass index (BMI), smoking status, oral contraceptive use, 
alcohol use, births after age 24) were added to the model.  All genotype main effects were 
examined for effect measure modification by alcohol use, BMI, smoking, births after age 24, oral 
contraceptive use, and age based on likelihood ratio tests and interaction contrast ratios (for 
departures from multiplicative and additive prevalences, respectively).
4. Results
Among 583 African Americans, 421 (72%) had at least one fibroid detected, and 24% had large 
fibroids.  Among 404 Whites, 201 (50%) had at least one fibroid, and 11% had large fibroids 
(Table 1).  
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COMT genotypes varied by race.  Among African Americans, 47% were Val/Val, 43% 
were Val/Met, and 10% were homozygous variant Met/Met.  For Whites, 24% were Val/Val, 50% 
were Val/Met, and 26% were Met/Met.  Distributions of COMT genotypes among noncases 
within each racial group were consistent with Hardy Weinberg Equilibrium.
In general, estimated prevalence ratios for fibroids in association with one or two copies 
of the Met allele versus the Val/Val genotype were close to the null for both African American 
and White women (Table 2).  Estimated prevalence ratios for small, medium, or large fibroids in 
association with the Met allele also were close to null, with the exception of an inverse 
association between the Met allele and small fibroids (versus no fibroids) among African 
Americans (PR=0.74; 95%CI:0.54,1.03).  Adjusting for potential confounders did not alter 
estimates 10%; therefore, final models included genotype only.  Interaction contrast ratios were 
all close to 0 (consistent with additive scale homogeneity)14, and likelihood ratio test p-values 
were all above 0.28 (consistent with multiplicative scale homogeneity) for the potential effect 
measure modifiers examined. 
5. Discussion
Fibroids disproportionately affect African Americans compared with Whites10,15-18.  Our 
study included 583 African Americans, who were more likely than White participants to have 
fibroids and the wildtype COMT Val/Val genotype; however the Val158Met polymorphism was 
not significantly related to prevalent fibroids among African American or White women in this 
study.  
Al- Hendy et al. reported a positive association between fibroids and the Val/Val versus 
Met/Met genotype (odds ratio=2.5; 95%CI:1.02,6.15)9 in a study that compared 186 cases (59 
White, 81 African American, 46 Hispanic) that underwent hysterectomy for “symptomatic 
uterine fibroids” and had two or more histologically confirmed fibroids to 142 controls 
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undergoing hysterectomy for cervical dysplasia, benign ovarian masses, or dysfunctional uterine 
bleeding.  In contrast, our study included 423 African American and 201 White women with 
ultrasound evidence of fibroids (both symptomatic and asymptomatic), and 162 African 
American and 203 White women with no fibroids detected who were representative of members 
of a large health plan, rather than women undergoing hysterectomy. In addition, we estimated 
prevalence ratios instead of prevalence odds ratios, which may exaggerate associations with 
common outcomes 13,14 such as fibroids.  We stratified analyses by race and grouped Val/Met and 
Met/Met genotypes together to increase sample size, but also found that fibroids were not 
associated with the Met/Met versus Val/Val genotype in the total population (PR=0.87; 
95%CI:0.75,1.02), or among African Americans (PR=1.00, 95%CI:0.85,1.18), or Whites 
(PR=1.02, 95%CI:0.77,1.35).  We had >80% power to detect a statistically significant (=0.05) 
PR>1.16 for fibroids versus no fibroids in association with Val/Val versus Val/Met or Met/Met
genotypes in African Americans, and >80% power to detect a PR>1.43 in Whites.         
Our findings do not rule out an association with fibroids treated by hysterectomy, but 
large fibroids, which are more likely to lead to hysterectomy19, were not associated with 
Val158Met in our study.  We cannot rule out associations between prevalent fibroids and other 
COMT variants; therefore future research should evaluate additional polymorphisms, as well as 
other genes in the estrogen metabolism pathway.
51
6. References
1. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and 
breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer 
Res 1997;57(1):81-6.
2. Yue TL, Wang X, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK, Lysko PG, 
Feuerstein GZ. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces 
apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated 
protein kinase signaling pathway and Fas expression. Mol Pharmacol 1997;51(6):951-62.
3. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS. 2-
Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen 
receptors alpha and beta. Cancer Res 2002;62(13):3691-7.
4. Pribluda VS, Gubish ER, Jr., Lavallee TM, Treston A, Swartz GM, Green SJ. 2-
Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. 
Cancer Metastasis Rev 2000;19(1-2):173-9.
5. Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and catechols. Journal 
of Biology and Chemistry 1958;233:702-705.
6. Hong CC, Thompson HJ, Jiang C, Hammond GL, Tritchler D, Yaffe M, Boyd NF. 
Val158Met Polymorphism in catechol-O-methyltransferase gene associated with risk 
factors for breast cancer. Cancer Epidemiol Biomarkers Prev 2003;12(9):838-47.
7. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk 
associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, 
CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 
1999;59(19):4870-5.
8. Thompson PA, Shields PG, Freudenheim JL, Stone A, Vena JE, Marshall JR, Graham S, 
Laughlin R, Nemoto T, Kadlubar FF, Ambrosone CB. Genetic polymorphisms in 
catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 
1998;58(10):2107-10.
9. Al- Hendy A, Salama SA. Catechol-O-methyltransferase polymorphism is associated with 
increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig 
2006;13(2):136-44.
10. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence 
of uterine lieomyoma in black and white women:  ultrasound evidence. American Journal 
of Obstetrics and Gynecology 2003;188(1):100-107.
11. Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology 
2003;14(2):247-250.
52
12. Ross P, Hall L, Smirnov I, Haff L. High level multiplex genotyping by MALDI-TOF 
mass spectrometry. Nature Biotechnology 1998;16(13):1347-1351.
13. Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the 
analysis of cross sectional data: what is to be done? Occup Environ Med 1998;55(4):272-
7.
14. Rothman K, Greenland S. Modern Epidemiology, Ed 2. Philadelphia: Lippincott-Raven, 
1998.
15. Kjerulff KH, Lagenberg P, Seidman JD, Stolley PD, Guzinski GM. Uterine leiomyomas: 
racial differences in severity, symptoms and age at dianosis. Journal of Reproductive 
Medicine 1996;41(7):483-490.
16. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, 
Willett WC, Hunter DJ. Variation in the incidence of uterine leiomyoma among 
premenopausal women by age and race. Obstetrics and Gynecology 1997;90(6):967-973.
17. Faerstein E, Szklo M, Rosenshein N. Risk factors for uterine leiomyoma:  a practice-
based case-control study.  I.  African-American heritage, reproductive history, body size, 
and smoking. American Journal of Epidemiology 2001;153(1):1-10.
18. Chen C-R, Buck GM, Courey NG, Perez KM, Wactawski-Wende J. Risk factors for 
uterine fibroids among women undergoing tubal sterilization. American Journal of 
Epidemiology 2001;153(1):20-26.
19. Wegienka G, Baird DD, Hertz-Picciotto I, Harlow SD, Steege JF, Hill MC, Schectman 
JM, Hartmann KE. Self-reported heavy bleeding associated with uterine leiomyomata. 
Obstetrics and Gynecology 2003;101(3):431-437.
53
Table 4.1. Characteristics of premenopausal study participants by race and fibroid status, National Institute of Environmental 
Health Science Uterine Fibroid Study
Fibroid Status
All Women African American Caucasian
Characteristics
No 
Fibroids
Fibroids 
present
No 
Fibroids
Small Medium Large No 
Fibroids
Small Medium Large
Total 350 622 155 94 187 140 195 70 87 44
Age
35-39 161 (46.0) 186 (29.9) 78(50.3) 37(39.4) 65(34.8) 36(25.7) 83(42.6) 19(27.1) 18(20.7) 11(25.0)
40-44 125 (35.7) 215 (34.6) 52(33.5) 33(35.1) 72(38.5) 47(33.6) 73(37.4) 17(24.3) 31(35.6) 15(34.1)
>=45 64 (18.3) 221 (35.5) 25(16.1) 24(25.5) 50(26.7) 57(40.7) 39(20.0) 34(48.6) 38(43.7) 18(40.9)
BMI
Normal 168 (48.0) 208 (33.4) 52(33.5) 19(20.2) 40(21.4) 36(25.7) 116(59.5) 39(55.7) 55(63.2) 19(43.2)
Overweight 94 (26.9) 178 (28.6) 45(29.0) 29(30.9) 52(27.8) 51(36.4) 49(25.1) 14(20.0) 18(20.7) 14(31.8)
Obese 88 (25.1) 236 (37.9) 58(37.4) 46(48.9) 95(50.8) 53(37.9) 30(15.4) 17(24.3) 14(16.1) 11(25.0)
Smoking Status
Never Smoked 194 (55.4) 310 (50.2) 79(51.0) 41(43.6) 80(42.8) 75(53.6) 115(59.0) 44(62.9) 46(52.9) 24(54.5)
Past Smoker 99 (28.3) 170 (27.5) 32(20.6) 19(20.2) 50(26.7) 32(22.9) 67(34.4) 22(31.4) 32(36.8) 15(34.1)
Current Smoker 57 (16.3) 138 (22.3) 44(28.4) 33(35.1) 56(29.9) 31(22.1) 13(6.7) 4(5.7) 9(10.3) 5(11.4)
Oral Contraceptive 
Use
Never Used OC 51 (14.6) 64 (10.3) 19(12.3) 5(5.3) 12(6.4) 12(8.6) 32(16.4) 10(14.3) 16(18.4) 9(20.5)
Current/Past User 
Of OC
299 (85.4) 558 (89.7) 136(87.7) 89(94.7) 175(93.6) 128(91.4) 163(83.6) 60(85.7) 71(81.6) 35(79.5)
54
Fibroid Status
All Women African American Caucasian
Characteristics
No 
Fibroids
Fibroids 
present
No 
Fibroids
Small Medium Large No 
Fibroids
Small Medium Large
Number of Fullterm 
Births after age 24
None 182 (52.0) 359 (57.7) 70(45.2) 48(51.1) 98(52.4) 75(53.6) 112(57.4) 44(62.9) 57(65.5) 37(84.1)
1 85 (24.3) 151 (24.3) 52(33.5) 31(33.0) 52(27.8) 45(32.1) 33(16.9) 7(10.0) 14(16.1) 2(4.5)
2 66 (18.9) 98 (15.8) 24(15.5) 12(12.8) 30(16.0) 18(12.9) 42(21.5) 18(25.7) 16(18.4) 4(9.09)
3 Or More 17 (4.9) 14 (2.3) 9(5.8) 3(3.2) 7(3.7) 2(1.4) 8(4.1) 1 (1.43) 0 (0) 1 (2.27)
Number of Alcoholic 
Drinks per Week
<0.5 111 (34.4) 246 (27.2) 76(49.0) 47(50.0) 98(52.4) 76(54.3) 35(17.9) 20(28.6) 22(25.3) 14(31.8)
0.5-<3 95 (29.4) 138 (23.7) 38(24.5) 22(23.4) 35(18.7) 25(17.9) 57(29.2) 21(30.0) 25(28.7) 9(20.5)
3-<7 60 (18.6) 103 (17.7) 16(10.3) 12(12.8) 18(9.6) 18(12.9) 44(22.6) 20(28.6) 21(24.1) 8(18.2)
7 Or More 57 (17.7) 95 (16.3) 11(7.1) 12(12.8) 22(11.8) 12(8.6) 46(23.6) 4(5.7) 9(10.3) 3(6.8)
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Table 4.2.  Prevalence ratios and 95% Confidence Intervals (CI) for the association between COMT Val158Met
genotypes and uterine fibroids in African American and White premenopausal participants in the Uterine Fibroid 
Study
Fibroid 
Status
African Americans Caucasians
Val/Val Val/Met & 
Met/Met
Val/Val Val/Met & 
Met/Met
N % N % RR  (95% CI) N % N % RR  (95% CI)
No Fibroids 65 23.7 90 29.2 1.00 47 49.0 148 48.1 1.00
Any Fibroids 206 75.2 214 69.5 0.96 (0.92, 1.01) 47 49.0 154 50.0 1.01  (0.90, 1.13)
Small 51 18.6 43 14.0 0.86 (0.73, 1.01) 14 14.6 56 18.2 1.09 (0.85, 1.41)
Medium 86 31.4 100 32.5 0.96 (0.87, 1.06) 23 24.0 64 20.8 0.96 (0.79, 1.17)
Large 69 25.2 71 23.1 0.93  (0.82, 1.04) 10 10.4 34 11.0 1.03 (0.75, 1.42)
F. Polymorphisms and Haplotypes of Cytochrome P-450 1A1 and 1B1, and Prevalence of 
Uterine Leiomyomata
1. Abstract
Uterine leiomyomata (fibroids) are hormone-dependent tumors that disproportionately 
affect African Americans compared to Whites.  Single nucleotide polymorphisms (SNPs) in 
Cytochrome P-450 1A1 (CYP1A1) and 1B1 (CYP1B1) encode enzymes that could affect 
estrogen’s biologic ability to influence fibroid development.  This study examined the relation 
between fibroid prevalence and common SNPs and haplotypes of CYP1A1 (*2A, *3, *2C, *4) 
and CYP1B1 (CYP1B1AS, CYP1B1LV).  Relations between polymorphisms and fibroid size 
(small, medium, or large versus none) were also determined.  The study population included a 
cross-sectional sample of premenopausal African American (n=583) and White (n=404) women 
who participated in the National Institute of Environmental Health Science’s Uterine Fibroid 
Study.  Blood was collected from participants for DNA, and telephone interviews and 
questionnaires were completed to gather demographic and reproductive history.  Prevalence 
ratios (PR) and prevalence differences (PD) were estimated using race-specific log-risk and 
linear-risk regression models.  Effect measure modification by age, body mass index, oral 
contraception use, fullterm births, smoking and alcohol use was evaluated.  Distributions of 
genotypes and fibroid prevalence varied by race.  An association between fibroids and variants of 
CYP1A1*3 (PR=1.14; 95%CI: 1.02, 1.28) was observed among African Americans.  
CYP1A1*2C variants tended to be associated with a reduction in the PR among Whites (0.79; 
95%CI: 0.54, 1.18).  The PRs for the association between CYP1A1*4 variants and fibroids were 
elevated among Whites (PR=1.20; 95%CI: 0.90, 1.61) and African Americans (PR=1.16; 95%CI:
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0.92, 1.48).  Haplotypes containing the above variants showed similar results.  No associations 
were observed between fibroids and CYP1B1 variants.  Adjusting for potential confounders did 
not alter effect estimates 10% and were therefore not included in final models.  Analysis of 
effect measure modification did not show deviations from additive or multiplicative expectations.  
Our results reveal possible relations between fibroid prevalence and polymorphisms of 
CYP1A1*3 and *4 in African Americans and CYP1A1 *2C and *4 in Whites; however, results 
should be interpreted with caution due to the potential for non-causal associations, and future 
studies should include a more comprehensive assessment of variation in CYP1A1 and CYP1B1, 
in addition to other estrogen metabolism genes that may influence the pathogenesis of uterine 
fibroids.  
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2. Introduction
Uterine leiomyomata, or fibroids, are the most common reproductive tract tumors in women1, 
and they affect a substantially higher proportion of African American women than White 
women2-6.  Although these smooth muscle tumors are benign, they are associated with significant 
morbidity and are the leading indication for hysterectomy in the United States7,8.  Fibroids also 
are associated with dysmenorrhea, menorrhagia, and possibly infertility1.  The causes of fibroids 
are unknown; however, clinical evidence suggests that they are strongly influenced by sex 
hormones, notably estrogen9,10.  
Estrogen metabolism may affect uterine fibroids by influencing exposure to estrogen and 
metabolites with estrogenic activity, or by influencing the formation of reactive catechol 
estrogens that may cause oxidative damage. Cytochrome P450 enzymes catalyze Phase I 
hydrozylation of estradiol.  More specifically, CYP1A1 enzymes catalyze hydrozylation at the 2 
carbon position (2-hydroxyestradiol) and CYP1B1 enzymes catalyze hydrozylation at the 4 
carbon position (4-hydroxyestradiol).  Hydrozylation at either position generates catechol 
estrogens and metabolites that vary in their ability to stimulate estrogen receptors and/or induce 
oxidative damage11.  4-hydroxyestradiol metabolites are more estrogenic (with respect to 
estrogen receptor activation) and are more likely to result in mutagenic DNA adducts than 2-
hydroxyestradiol metabolites12,13.       
Polymorphisms that influence estrogen metabolism enzymes might influence fibroid 
tumorigenesis by influencing estrogen hydrozylation and the production of estrogenic by-
products or DNA adducts. Several common polymorphisms have been identified in CYP1A1 and 
CYP1B114,15.  CYP1A1*2C (A>G; rs1048943) and *4 (C>A; rs1799814) in the heme-binding 
region cause amino acid substitutions of isoleucine to valine, and threonine to asparagine, 
respectively.  CYP1A1*2C has been associated with other estrogen mediated tumors, such as 
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breast cancer16, although not all breast cancer studies have found an association17,18.  The 
functional significance of CYP1A1*2A (T>C) and *3 (T>C) variants in the 3’ non-coding 
region19,20 is unknown, however CYP1A1*2A has been reported to be in linkage disequilibrium
with the non-synonymous *2C variant14,15,21-23, and the *3 variant is very common among 
African Americans18 who are at increased risk of fibroids2-6. Some24,25 but not all18,26,27 studies 
have associated CYP1A1*2A with breast cancer, which is also believed to be an estrogen 
dependent tumor28,29.  
CYP1B1 Leu432Val (G>C; rs1056836) and Ala119Ser (G>T; rs1056827) are located in 
exons 3 and 2 respectively.  The Leu432Val polymorphism results in a leucine to valine amino 
acid substitution that increased 2 and 4-hydroxylation of estradiol by at least three-fold in cells 
isolated from Escherichia coli30. Ala119Ser results in an amino acid change of alanine to serine, 
but has not been shown to alter enzyme function31. Previous studies have found associations 
between breast cancer and CYP1B1 Ala119Ser32and Leu432Val33; however, associations with 
Leu432Val have been inconsistent32,34. 
The present study evaluated the relation between several common polymorphisms 
(CYP1A1*1, CYP1A1*2, CYP1A1*3, CYP1A1*4, CYP1B1 Ala119Ser, and CYP1B1 Leu432Val) 
and the prevalence of uterine fibroids in a population-based cross-sectional study of 
premenopausal women.  In addition, we examined associations with estimated CYP1A1 and 
CYP1B1 haplotyes and evaluated effect measure modification by factors that may influence 
fibroids or estrogen metabolism.
3. Methods
Study Population
Data for this study are from the National Institute of Environmental Health Sciences Uterine 
Fibroid Study (UFS), which was conducted in collaboration with the George Washington 
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University Medical Center.  UFS participants were randomly selected women from a prepaid 
urban health plan, chosen because of its substantial black membership and broad socioeconomic 
base.   To be eligible, participants had to be aged 35-49 years, English speaking, and a member of 
the health plan’s Washington, DC site.  Eighty percent of eligible women participated (N=1430)3.  
This analysis was restricted to premenopausal UFS participants (n=1245) (defined as women 
who, at enrollment, had reported a menstrual period, pregnancy, or breastfeeding during the 
previous twelve months) that had available DNA for genotyping (N=1064) and self-reported 
either African American or White race, giving a final sample of 987.  
Outcome Assessment
Fibroids 0.5cm in diameter or larger were identified by transabdominal and transvaginal 
ultrasounds performed by sonographers certified by the American Registry of Diagnostic 
Medical Sonographers, under the supervision of a radiologist trained in ultrasonography.  
Radiology records were used to assess fibroid status for women with a recent pelvic ultrasound 
examination done at the study site for clinical purposes.  The size of the largest fibroid among 
women who had fibroids was categorized as small (diameter 2 cm or less), medium (diameter >2 
to < 4 cm), or large (diameter 4 cm or larger).
Assessment of Genotype and Covariates
Fasting whole blood samples were collected from participants during a clinic visit (74% of 
the parent study population) and sent to an outside laboratory (BioServe Biotechnologies, Laurel, 
MD) for genotyping.  DNA was extracted from whole blood using a modified salt precipitation 
DNA extraction kit, GeneQuick (manufactured by BioServe Biotechnologies, Laurel, MD).  
Polymorphisms of CYP1A1 and CYP1B1 were identified using matrix-assisted laser 
desorption/ionization time-of-flight mass spectometry (MALDI-TOF MS), a high throughput, 
accurate technique that simultaneously performs multiple genotyping analyses on very small 
quantities of DNA35.  Assays failed for less than 2% of all participants for each SNP.  Repeat 
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samples were run for 30 randomly selected participants to assess genotyping error.  Of 180 paired 
repeats, 5 failed to amplify on one of the two assays; all other pairs were concordant.   
Data were collected on other factors known or suspected to be related to fibroids.  Participant 
characteristics, such as age, race, and alcohol use were collected by a self-administered 
questionnaire. Trained staff conducted telephone interviews to collect data on oral contraceptive 
use, smoking, and reproductive history and height.  Weight was measured at a clinic visit. The 
number of births after age 24, which was found to be inversely associated with fibroids in a 
previous analysis from this study36, was determined from responses to the interview.     
Data Analysis
Distributions of CYP1A1 and CYP1B1 polymorphisms were evaluated for consistency with 
Hardy Weinberg Equilibrium among noncases.  Pairwise linkage disequilbrium (r2) was 
estimated for pairs of CYP1A1 single nucleotide polymorphisms (SNPs) and CYP1B1 SNPs37,38. 
Haplotypes, defined by the measured SNPs (4 in CYP1A1 and 2 in CYP1B1), were inferred using 
the PHASE program (version 2.0.2)39,40, which estimates the most probable haplotype pair (or 
diplotype) for each observation and the posterior probability of each inference.  Each allele at 
each of the 4 loci 5’ to 3’ for CYP1A1, and the 2 loci 5’ to 3’ for CYP1B1 compose the haplotype 
for each gene.  To reduce error due to random variation, haplotypes with posterior probabilities 
less than 90% were excluded from haplotype analyses (n=111 African Americans missing data 
for CYP1B1 haplotypes). Women missing more than one SNP for CYP1A1 (2 African American 
and 1 White woman), and women without complete SNP data for CYP1B1 (6 African American 
and 2 White women) also were excluded.  The analysis groups for were similar in study 
characteristics to the total study populations (581 African Americans and 403 Whites for 
CYP1A1 haplotype analysis, 466 African Americans and 402 for CYP1B1 haplotype analysis). 
 All parameter estimates were obtained using SAS 8.0 (Statistical Analytic Systems, Version 
8.0; SAS Institute, Inc., Cary, NC; 1999).  Race-specific log-risk and linear-risk regression 
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models were used to determine prevalence ratios (PR) and prevalence differences (PD)41,42 for 
fibroids in association with variant versus wild type genotypes among African American and 
White women.  Separate regression models were used to determine associations between fibroids 
and haplotypes, with the most frequent haplotype used as the reference group.  Haplotypes and 
diplotypes that were inferred in five or fewer women in either racial group were not included in 
regression analyses.   Separate log-risk models were used to estimate prevalence ratios for 
associations between genotypes and the size of the largest fibroid (small fibroids, medium 
fibroids, and large fibroids relative to no fibroids, respectively).  All genotype main effects were 
examined for effect measure modification by alcohol use (number of drinks per week <0.5, 0.5-
<3, 3-<7, 7 or more), body mass index (<25, 25-29.99, or >30 kg/m2) smoking (never, past, 
current), fullterm births after age 24 (0, 1, 2, 3 or more), oral contraceptive use (never, 
current/past use), and age (35-39, 40-44, 45 or older).  Effect modification was evaluated by 
comparing joint effect estimates for each main predictor (e.g. polymorphism or haplotype) and 
the potential modifier based on likelihood ratio tests (for departures from multiplicative 
prevalences,  = 0.20) and interaction contrast ratios (for departures from additive prevalences). 
Confounding (by alcohol use, body mass index, smoking, fullterm births after age 24, oral 
contraceptive use, and age) was evaluated based on a 10% or greater change in the estimated 
prevalence ratio when the potential confounder was included in the model. None of the potential 
confounders met this criterion; consequently results are reported for race-specific models that 
included genotypes only.  
4. Results
A total of 583 African American and 404 White participants were included in this analysis.  
The mean age was 42.2 (sd. 4.07) for cases and 40.6 (sd. 3.89) for noncases.  Approximately 
72% of African American and 50% of White participants had fibroids detected by ultrasound 
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(Table 4.3).  White and African American women were equally likely to have small fibroids 
(17% vs. 16%) but Whites were less likely to have medium (22% vs. 32%) or large fibroids (11% 
vs. 24%) than African American women.  
The distributions of variant alleles in African American and White participants (respectively) 
were: 39% and 24% for CYP1A1*2A, 14% and 0.5% for CYP1A1*3, 2% and 10% for 
CYP1A1*2C, 2% and 9% for CYP1A1*4, 73% and 49% for CYP1B1AS and 44% and 83% for 
CYP1B1LV.  We did not find evidence of linkage disequilibrium among the four CYP1A1 or two 
CYP1B1 polymorphisms among African American women, but, consistent with previous 
studies14,15,21-23, CYP1A1*2A and CYP1A1*2C were linked among White women (r2=0.34).  
The prevalence of fibroids was increased among African Americans with one or more variant 
CYP1A1*3 allele (Table 4.2, PR=1.14; 95%CI: 1.02, 1.28; PD=0.10; 95%CI: 0.01, 0.19), but the 
association between CYP1A1*3 and fibroids among Whites was not estimated due to small 
numbers. The CYP1A1*4 CA or AA genotype was positively associated with prevalent fibroids 
among both Whites (PR=1.20; 95%CI: 0.90, 1.61; PD=0.10; 95%CI: -0.07, 0.27) and African 
Americans (PR=1.16; 95%CI: 0.92, 1.48; PD=0.12; 95%CI: -0.08, 0.32). The CYP1A1*2C 
variant tended to be inversely associated with fibroids among White women (PR=0.79; 95%CI:  
0.54, 1.18; PD=-0.11; 95%CI: -0.27, 0.06) but not among African American women. 
Associations were not evident between fibroids and the CYP1A1*2A variant or the two CYP1B1
variants among women in either racial group. 
Analyses of effect measure modification by BMI, alcohol use, births after age 24, smoking, 
oral contraceptive use, and age were consistent with expectations for additive and multiplicative 
joint effects with gene variants (Table A.35 - A.43).  Prevalence ratio estimates for individual 
SNPs in association with fibroids categorized according to the size of the largest fibroid (small, 
medium or large compared with no fibroids) were consistent with associations estimated for each 
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SNP and fibroids as a whole, with little evidence of variation beyond what might be accounted 
for by chance (Table 4.5).
Associations between fibroids and estimated CYP1A1 and CYP1B1 haplotypes and 
diplotypes were consistent with findings for individual SNPs (Table 4.6). Specifically, 
haplotypes and diplotypes that included the CYP1A1*4 A allele were positively associated with 
fibroids in African Americans (TTAA PR=1.17; 95%CI: 0.93, 1.49; PD=0.13; 95%CI: -0.07, 
0.32; TTAC/TTAA PR=1.25; 95%CI=1.01, 1.56; PD=0.18; 95%CI: -0.01, 0.37) and Whites 
(TTAA PR=1.18; 95%CI=0.87, 1.56; PD=0.08; 95%CI: -0.09, 0.25; TTAC/TTAA PR=1.14; 
95%CI: 0.83, 1.56; PD=0.07; 95%CI: -0.11, 0.25).  Similarly, haplotypes and diplotypes that 
included the CYP1A1*3 C allele were positively associated with fibroids in African Americans 
(TCAC PR=1.13; 95%CI: 1.01, 1.26; PD=0.09; 95%CI: 0.01, 0.18). Haplotypes and diplotypes 
that included the CYP1A1*2C G allele were inversely associated with fibroids in Whites (CTGC
PR=0.84; 95%CI: 0.58, 1.22; PD=-0.08; 95%CI: -0.24, 0.08; TTAC/CTGC PR=0.71; 0.45, 1.15; 
PD=0.14; 95%CI: -0.32, 0.03) and to a lesser extent in African Americans (CTGC PR=0.92; 
95%CI: 0.58, 1.47; PD=-0.05; 95%CI: -0.36, 0.26; TTAC/CTGC PR=0.87; 0.51, 1.49; PD=-0.09; 
95%CI: -0.43, 0.25).  There was a weak inverse association between the CYP1B1 TC/TC 
diplotype and fibroids among both African Americans (PR=0.86; 95%CI: 0.60, 1.23; PD=-0.11; 
95%CI: -0.35, 0.13) and Whites (PR=0.91; 95%CI: 0.91; 0.58, 1.43; PD=-0.05; 95%CI: -0.26, 
0.17); otherwise, estimated associations for CYP1B1 haplotypes and diplotypes were close to the 
null.
5. Discussion
Uterine fibroids are only diagnosed after menarche9 and diminish in size or disappear after 
menopause1,10.  In addition, estrogen receptor levels in fibroid tumor cells are significantly 
elevated compared with normal myometrial cells during the follicular phase43, and 4-
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hydroxyestradiol levels are increased in leiomyoma compared with normal surrounding tissue44.  
We therefore hypothesized that polymorphisms in estrogen metabolism genes might influence the 
prevalence of uterine fibroids by influencing levels of estrogenic (and potentially mutagenic) 
byproducts of estrogen metabolism. Gene variants that differ by race might also contribute to 
differences in the prevalence of uterine fibroids between African Americans and Whites. 
Our results support an association between fibroids and the CYP1A1*3 variant, which is 
found almost exclusively in African American women (14% of our African American study 
population) (PR=1.14; 95%CI: 1.02, 1.28; PD=0.10 95%CI: 0.01, 0.19). However, this 
polymorphism is located in a non-coding region of the gene, suggesting an association due to 
linkage with a causal variant, or a non-causal association due to chance or error. The 
CYP1A1*2C variant, which was less common among African Americans than Whites in our 
population (2% vs 10%), was inversely associated with fibroids only among White women when 
evaluated as a single SNP (PR=0.79; 95%CI: 0.54, 1.18 and PD=-0.11; 95%CI=-0.27, 0.06 in 
Whites; PR=0.96; 95%CI: 0.64, 1.44 and PD=-0.03; 95%CI: -0.32, 0.26 in African Americans), 
though there was a weak inverse association with fibroids among both White and African 
American women for haplotypes and diplotypes that included the variant SNP (CTGC and 
TTAC/CTGC). This variant has been positively associated with breast cancer in some previous 
studies16,27, but associations have been null in others17,18.  Thus, the direction of the association 
observed with fibroids was unexpected. We noted positive associations between the CYP1A1*4
variant and fibroids among both African American (PR=1.16; 95%CI: 0.92, 1.48; PD=0.12; 
95%CI: -0.08, 0.32) and White women (PR=1.20; 95%CI: 0.90, 1.61; PD=0.10; 95%CI: -0.07, 
0.27), with positive associations also noted for haplotypes and diplotypes that included this 
variant (TTAA and TTAC/TTAA). This variant is associated with an amino acid change, but 
estimated associations with other hormonally-mediated cancers (such as breast17,18 and 
endometrial45) have been null.  It was somewhat less common in African American than Whites 
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(2% vs. 9%), thus it would not help explain the increased prevalence of fibroids in African 
American women. 
We did not find evidence of associations between prevalent fibroids and two common SNPs 
in CYP1B1, both of which are associated with amino acid changes. During estrogen metabolism, 
hydroxylation at the 4-carbon position, which is catalyzed primarily by CYP1B1, produces 
metabolites that are more estrogenic and potentially mutagenic than 2-hydroxyestradiol 
metabolites that are more likely to be byproducts of CYP1A1 metabolism; consequently, evidence 
of associations with CYP1A1 but not CYP1B1 variants are contrary to our prior expectations. 
However, we evaluated only two SNPs in CYP1B1, and an association with other variants cannot 
be ruled out. 
We did not find evidence to support associations between the genotypes evaluated and the 
size of the largest fibroid detected. Evidence of stronger associations with larger fibroids would 
have been consistent with an effect of gene variants on fibroid growth, while a lack of 
associations with fibroid size was consistent with an effect early in pathogenesis.  However, we 
were unable to evaluate associations with the number of fibroids or the average size of fibroids 
among women with multiple fibroids, and estimates were imprecise due to small numbers of 
observations within each size category. 
Our study included a large number of African American women, who are disproportionately 
affected by fibroids2-6 compared with Whites.  Nonetheless, we had limited power to estimate 
race-specific prevalences for uncommon SNPs.  We inferred haplotypes based on the Markov-
Chain Monte Carlo algorithm, which assigns a posterior probability for the accuracy of the 
inference based on the measured SNPs, but gene coverage was sparse, and we had limited power 
to examine rare haplotypes and diplotypes.  In addition, a large proportion of African American 
women (n=111) were excluded from CYP1B1 haplotype analyses because posterior probabilities 
were less than 90%.   
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Since most fibroids are asymptomatic, determination of fibroid status has proven to be 
difficult in research46. The UFS study used ultrasound screening to identify fibroids, which 
improved upon the diagnostic methods of previous studies. Ultrasound examination, the standard 
non-invasive clinical method for diagnosis, has a reported sensitivity of 67-99% and specificity 
of 89-94% when operative hysteroscopy and histological classification is used as the gold 
standard47-49.  
In summary, we noted positive associations between fibroids and CYP1A1*3 and *4 variants 
among African Americans, and between fibroids and CYP1A1*2C and *4 variants in Whites.
Although the magnitudes of the estimated prevalence ratios for the association between fibroids 
and these gene variants were modest, prevalence difference estimates show the potential for a 
substantial impact for these variants on the prevalence of fibroids among both African American 
and White women. These apparent inconsistencies highlight the importance of estimating 
absolute differences when the prevalence of an outcome is high, as was the case in our cross-
sectional population of premenopausal women. Nonetheless, these associations must be 
interpreted with caution given the potential of non-causal relations due to chance or bias. Clear 
associations were not seen between CYP1B1 SNPs and prevalent fibroids; however, we evaluated 
only two polymorphisms within this gene. To our knowledge, our study was the first to evaluate 
associations between CYP1A1 and CYP1B1 polymorphisms and fibroids, and our findings must 
therefore be replicated in other populations.  In addition, future research should consider a more 
comprehensive evaluation of variants throughout the CYP1A1  and CYP1B1 genes, in addition to 
evaluating other genes in the estrogen metabolism pathway that may influence the pathogenesis 
of fibroids, which are a major cause of morbidity among all women.
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Table 4.3. Characteristics of premenopausal African American and White participants in the 
cross-sectional National Institutes of Environmental Health Sciences Uterine Fibroid Study with 
genotype dataa
Fibroid Status
African Americans Whites
Characteristics
Fibroid 
Present
Total Fibroid 
Prevalence
Fibroid 
Present
Total Fibroid 
Prevalence
Total 421 583 0.72 201 404 0.50
Age (years)
35-39 138 220 0.63 48 137 0.35
40-44 152 206 0.74 63 136 0.46
>=45 131 157 0.83 90 131 0.69
BMI (kg/m2)
Normal (<25) 95 148 0.64 113 237 0.48
Overweight (25-29.9) 132 179 0.74 46 95 0.48
Obese (>30) 194 256 0.76 42 72 0.58
Smoking Status
Never Smoked 124 277 0.45 114 234 0.49
Past Smoker 101 134 0.75 69 139 0.50
Current Smoker 120 168 0.71 18 31 0.58
Oral Contraceptive Use
Never Used OC 29 48 0.60 35 69 0.51
Current/Past User Of OC 392 535 0.73 166 335 0.50
Fullterm Births after age 
24
None 221 296 0.75 138 257 0.54
1 128 181 0.71 23 57 0.40
2 61 85 0.72 38 80 0.48
3 Or More 12 21 0.57 2 10 0.20
Number of Alcoholic 
Drinks per Week
<0.5 221 300 0.74 56 60 0.93
0.5-<3 82 122 0.67 55 115 0.48
3-<7 48 65 0.74 49 102 0.48
7 Or More 46 58 0.79 16 98 0.16
aPrevalent fibroids detected by ultrasound.
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Table 4.4. Estimated prevalence ratio(PR), prevalence differences (PD) and 95% confidence intervals (95% CI) for selected estrog
estrogen metabolism gene polymorphisms among premenopausal African American and White participants in the Uterine Fibroid Study
African Americans WhitesGenotype
Fibroid 
Present
Total Prev PR (95% CI) PD (95% CI) Fibroid 
Present
Total Prev PR  (95% CI) PD (95% CI)
CYP1A1*2A
TT 260 352 0.74 1.00 0 153 298 0.51 1.00 0
TC  or  CC 159 222 0.72 0.97 (0.87,1.08) -0.02 (-0.10,0.05) 47 97 0.48 0.94 (0.75, 1.19) -0.03 (-0.14, 0.09)
CYP1A1*3a
TT 352 492 0.72 1.00 0 200 393 0.51 **
TC  or  CC 67 82 0.82 1.14 (1.02,1.28) 0.10 (0.01, 0.19) 1 2 ** ** **
CYP1A1*2C
AA 412 564 0.73 1.00 0 183 355 0.52 1.00 0
AG or  GG 7 10 0.70 0.96 (0.64,1.44) -0.03 (-0.32, 0.26) 16 39 0.41 0.79 (0.54, 1.18) -0.11 (-0.27, 0.06)
CYP1A1*4
CC 408 561 0.73 1.00 0 180 361 0.50 1.00 0
CA or AA 11 13 0.85 1.16 (0.92,1.48) 0.12 (-0.08, 0.32) 21 35 0.60 1.20 (0.90, 1.61) 0.10 (-0.07, 0.27)
CYP1B1AS
GG 109 149 0.73 1.00 0 102 200 0.51 1.00 0
GT or TT 308 421 0.73 1.00 (0.90,1.12) 0.00 (-0.08, 0.08) 99 194 0.51 1.00 (0.83, 1.21) 0.00 (-0.10, 0.10)
CYP1B1LV
GG 237 321 0.74 1.00 0 32 66 0.48 1.00 0
GC or CC 182 253 0.72 0.97 (0.88,1.08) -0.02 (-0.09, 0.05) 169 330 0.51 1.06 (0.80, 1.38) 0.03 (-0.10, 0.16)
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Table 4.5. Estimated prevalence ratios (PR*) and 95% confidence intervals (95% CI) for the association between selected estrogen 
metabolism gene polymorphisms and uterine fibroids classified according to the size of the largest fibroid among premenopausal African 
American and White participants in the Uterine Fibroid Study
Fibroid Status
African Americans Whites
No 
Fibroids
Small Medium Large No 
Fibroids
Small Medium Large
Genotype
N N PR
(95% CI)
N PR
(95% CI)
N PR
(95% CI)
N N PR
(95% CI)
N PR
(95% CI)
N PR
 (95%CI)
Total 155 94 187 140 195 70 87 44
CYP1A1*2A
TT 92 61 1.00 115 1.00 84 1.00 145 52 1.00 66 1.00 35 1.00
TC or CC 63 32 0.84
(0.60,1.19)
71 0.95
(0.78,1.17)
56 0.99
(0.77, 1.26)
50 18 1.00
(0.63,1.59)
20 0.91
(0.60, 1.39 )
9 0.78 (0.40, 1.54)
CYP1A1*3
TT 140 79 1.00 157 1.00 116 1.00 193 70 87 43
TC or CC 15 14 1.33
(0.88,2.03)
29 1.25
(0.98,1.58)
24 1.36
(1.02,1.80)
1 0 ** 0 ** 1 **
CYP1B1AS
GG 40 24 1.00 46 1.00 39 1.00 98 38 1.00 43 1.00 21 1.00
GT or TT 113 70 1.02
(0.71,1.47)
138 1.03
(0.82,1.29)
100 0.95
(0.73,1.24)
95 32 0.90
(0.60,1.35)
44 1.04
(0.73,1.47)
23 1.10
(0.65,1.88)
CYP1B1LV
GG 84 51 1.00 104 1.00 82 1.00 34 11 1.00 14 1.00 7 1.00
GC or CC 71 43 1.00
(0.73,1.38)
81 0.96
(0.79,1.17)
58 0.91
(0.71,1.16)
161 59 1.10
(0.63,1.92)
73 1.07
(0.66,1.73)
37 1.09
(0.53,2.28)
*PR compare the prevalence of fibroids versus no fibroids for each size category in association with variant alleles. Estimates are not shown 
for CYP1A1*3 among Whites due to small numbers.
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Table 4.6. Estimated prevalence ratios (PR), prevalence differences (PD) and 95% confidence intervals (95% CI) for haplotypes and 
diplotypes based on selected estrogen metabolism gene polymorphisms among premenopausal African American and White participants in 
the Uterine Fibroid Study.
Fibroid Status
African Americans Whites
Genotype
Fibroid  
present
Total Prev PR (95% CI) PD (95% CI) Fibroid 
present
Total Prev PR (95%CI) PD (95%CI)
CYP1A1
haplotypesa
Total 838 1148 0.73 400 790 0.51
TTAC 579 803 0.72 Ref 0 327 648 0.50 Ref 0
CTAC 171 236 0.72 1.00 (0.92,1.10) 0.00 (-0.06,0.07) 35 66 0.53 1.06 (0.83, 1.34) 0.03 (-0.10,0.15)
CTGC 6 9 0.67 0.92 (0.58,1.47) -0.05(-0.36,0.26) 17 40 0.43 0.86 (0.58, 1.22) -0.08(-0.24,0.08)
TCAC 70 86 0.81 1.13 (1.01,1.26) 0.09 (0.01, 0.18) 1 2 ** ** **
TTAA 11 13 0.85 1.17 (0.93,1.49) 0.13 (-0.07, 0.32) 20 34 0.59 1.18 (0.87, 1.56) 0.08 (-0.09,0.25)
CYP1A1
diplotypesa
Total 400 574 0.70 201 396 0.51
TTAC/TTAC 200 278 0.72 Ref 133 263 0.51 Ref 0
CTAC/CTAC 17 22 0.78 1.07 (0.85,1.36) 0.05 (-0.13, 0.24) 1 3 ** ** **
TTAA/CTAC 1 2 ** ** ** 29 54 0.54 1.06 (0.81, 1.40) 0.03 (-0.11,0.18)
TTAC/CTAC 118 170 0.69 0.96 (0.85,1.09) -0.03(-0.11,0.06) 0 0 0 **
TTAC/CTGC 5 8 0.63 0.87 (0.51,1.49) -0.09(-0.43,0.25) 12 33 0.36 0.71 (0.45, 1.15) -0.14(-0.32,0.03)
TTAC/TCAC 46 58 0.79 1.10 (0.95,1.28) 0.07 (-0.04, 0.19) 1 2 ** ** **
TTAC/TTAA 9 10 0.90 1.25 (1.01, 1.56) 0.18 (-0.01, 0.37) 19 33 0.58 1.14 (0.83, 1.56) 0.07 (-0.11,0.25)
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Fibroid Status
African Americans Whites
Genotype
Fibroid  
present
Total Prev PR (95% CI) PD (95% CI) Fibroid 
present
Total Prev PR (95%CI) PD (95%CI)
CYP1B1 
haplotypesb
Total 678 918 0.74 402 788 0.51
GG 302 408 0.74 Ref 0 164 326 0.50 Ref 0
GC 49 65 0.75 1.04 (0.90,1.20) 0.01 (-0.10, 0.13) 126 241 0.52 1.04 (0.90, 1.20) 0.02 (-0.6,0.11)
TC 80 112 0.71 0.97 (0.87,1.12) -0.03(-0.12,0.07) 110 216 0.51 1.02 (0.94, 1.11) 0.01 (-0.07,0.10)
TG 247 333 0.74 1.00 (0.94,1.11) 0.00 (-0.06, 0.07) 2 5 ** ** **
CYP1B1
diplotypesb
Total 339 459 0.74 201 394 0.51
GG/TG 121 160 0.76 Ref 1 4 ** ** **
GG/GC 31 40 0.78 1.02 (0.85,1.24) 0.02 (-0.13, 0.16) 54 106 0.51 Ref
GC/GC 3 5 ** ** ** 17 32 0.53 1.04 (0.72,1.52) 0.02 (-0.18,0.22)
GC/TC 12 15 0.80 1.06 (0.81,1.38) 0.04 (-0.17, 0.26) 38 71 0.54 1.05 (0.79,1.40) 0.03 (-0.12,0.18)
GG/GG 75 104 0.72 0.95 (0.82, 1.11) -0.04(-0.14,0.07) 31 62 0.50 0.98 (0.72,1.34) -0.01(-0.17,0.15)
GG/TC 0 0 ** ** ** 47 92 0.51 1.00 (0.76, 1.32) 0.00 (-0.14,0.14)
TC/TC 11 17 0.65 0.86 (0.60,1.23) -0.11(-0.35,0.13) 12 26 0.46 0.91 (0.58,1.43) -0.05(-0.26,0.17)
TG/TC 46 63 0.73 0.97 (0.81,1.15) -0.03(-0.15,0.10) 1 0 ** ** **
TG/TG 40 55 0.73 0.96 (0.80,1.16) -0.03(-0.16,0.11) 0 0 ** ** **
aOrder of SNPs:  CYP1A1*2A, CYP1A1*3, CYP1A1*2C, CYP1A1*4
bOrder of SNPs:  CYP1B1 Ala119Ser, CYP1B1 Leu432Val
 **Not enough participants with this haplotype (or diplotype) to estimate associations. 
V. CONCLUSIONS
A. Overview of Study Purpose
Uterine leiomyomas, or fibroids, cause significant morbidity among premenopausal women1.  
They disproportionately affect African Americans compared with Whites.  In addition, fibroids 
among African Americans are larger and present with more symptoms than Whites2-4.  Although 
the causes of fibroids are unknown, clinical, molecular, and observational evidence suggests that 
they are hormonally dependent.  One hormone in particular that could be related to fibroid 
development is estrogen.
The biologic effect of estrogen depends, in part, on how it is metabolized.  Metabolism of 
estrogen primarily occurs in the liver, but can also occur in other tissues.  Estrogen hydroxylation 
at the C-2 position is catalyzed primarily by CYP1A1 enzymes, yielding the catechol estrogens
2-hydroxyestrone and 2-hydroxyestradiol (2-OH); likewise, hydroxylation at the 4 carbon (C-4) 
position is catalyzed primarily by CYP1B1 enzymes, yielding the catechol estrogens 4-
hydroxyestrone and 4-hydroxyestradiol (4-OH)5,6.  In general, initial hydroxylation at the C-4 
position leads to metabolites that are more estrogenic and potentially genotoxic than those 
produced by hydroxylation at the C-2 position8,9. Phase II conjugation reactions (methylation, 
glucuronidation, and sulfation) produce estrogen metabolites that may be excreted through the 
urine and feces, or be maintained in circulation.  Phase II methylation of 2-OH and 4-OH to less 
reactive metabolites (2-methoxyestrone and 2-methoxyestradiol, and 4-methoxyestrone and 4-
methoxyestradiol, respectively) by the COMT enzyme reduces the formation of highly reactive 
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quinones5,6, which are tumor promoters 7.  Variation in genes that encode estrogen metabolism 
enzymes may influence the pathogenesis of estrogen-dependent tumors, including fibroids.  
Our primary aim was to examine relations between fibroids and polymorphisms of CYP1A1, 
CYP1B1, and COMT genes that are involved in estrogen metabolism.  In addition, we inferred 
haplotypes for CYP1A1 and CYP1B1 and evaluated relations between these haplotypes and 
fibroids.  We hypothesized that genotypes with variant alleles that alter estrogen metabolism 
would be associated with the prevalence or size of uterine fibroids.   Given that CYP1B1 is 
primarily responsible for catalyzing reactions at the C-4 position, resulting in metabolites that 
may be more estrogenic or mutagenic than 2-hydroxy metabolites produced by CYP1A1 
metabolism8.9, we hypothesized that CYP1B1 variants might be more strongly associated with 
fibroids than variants in CYP1A1.  We also hypothesized that ethnic differences in the 
prevalence of estrogen metabolism gene polymorphisms might at least partly explain ethnic 
differences in the prevalence of uterine fibroids.   As a secondary aim, we examined whether 
prevalence effect estimates were modified by smoking status, age, alcohol use or BMI; 
specifically, we hypothesized that women with one or more variant alleles that also were 
smokers, obese, of older age, or that consumed alcohol would be more likely to have uterine 
fibroids than women who were not jointly exposed to a variant allele and one of these factors. 
We evaluated these hypotheses using data from the National Environmental and Health Sciences 
Uterine Fibroid Study (UFS), a cross sectional sample of women from an urban health plan.  
Log-risk and linear-risk regression models were constructed to determine prevalence ratio and 
prevalence difference estimates of the associations between prevalent fibroids and the genotypes 
of interest.
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B. Summary of Findings
There were a total of 583 African American and 404 White participants included in this 
study.  The mean age was 42.2 (sd. 4.07) for cases and 40.6 (sd. 3.89) for noncases.  
Approximately 64% of women in the study had fibroids, which were detected disproportionately 
in African American (73%), compared with White (51%) women.  Overall, the majority of 
women with detectable fibroids had fibroids that were 2-4 cm in diameter. Whites and African 
Americans were equally likely to have small fibroids (17% vs. 16%), but White participants less 
likely to have medium (22% vs. 32%) or large fibroids (11% vs. 24%) than African American 
participants.
The distribution s of CYP1A1, CYP1B1, and COMT polymorphisms were consistent with 
Hardy Weinberg Equilibrium among noncases.  The distributions of all gene variants varied by 
race. Approximately 60% of African American and White women were homozygous wildtype 
for CYP1A1*2A, while only 4% of African Americans and 2% of Whites were homozygous 
variant.  The overwhelming majority of African American and White women were homozygous 
wildtype for CYP1A1*2C (98% and 90% respectively), while only one white woman and no 
African American women were homozygous variant for CYP1A1*2C.  Approximately 86% of 
African American participants were homozygous wildtype, 14% were heterozygous, and <1% 
were homozygous variant for CYP1A1*3.  In contrast, over 99% of White participants were 
homozygous wildtype. The prevalence of variant alleles of CYP1A1*4 was slightly higher among 
Whites than African Americans.  More than 97% of African American were homozygous 
wildtype and less than 2% were heterozygous.  For Whites, approximately 91% were 
homozygous wildtype and 9% were heterozygous.
About one quarter of African American participants were homozygous wildtype for the 
CYP1B1 Ala119Ser polymorphism, while 50% were heterozygous. In contrast, about half of 
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White participants were homozygous wildtype for Ala119Ser, and only a third were
heterozygous.  Half of the African American participants were homozygous wildtype for the 
CYP1B1 Leu432Val polymorphism, while 37% were heterozygous and 7% were homozygous 
variant.  In contrast, only 17% of White participants were homozygous wildtype, while the 
majority had one or more variant alleles (51% heterozygous, 33% homozygous variant).  
Almost half of the African American participants were homozygous wildtype genotype for 
the COMT Val158Met polymorphism, 43% were heterozygous and 9.62% were homozygous 
variant.  Approximately one quarter of White participants were homozygous wildtype for this 
polymorphism, half were heterozygous, and one quarter were homozygous variant.
We found both positive and negative associations between polymorphisms and prevalent 
fibroids.  CYP1A1*3, a polymorphism almost exclusively found in African Americans11, was 
positively associated with fibroid prevalence (PD=0.10; 95%CI: 0.01, 0.19). CYP1A1*2C was 
inversely associated with fibroid prevalence in Whites (PD=-0.11; 95%CI: -0.27, 0.06), but was 
not clearly associated with fibroids in African Americans (PD=-0.03; 95%CI: -0.32, 0.26).  
CYP1A1*4 variant genotypes were positively associated with prevalent fibroids among women in 
both racial groups (PD for African Americans = 0.12, 95%CI: -0.08, 0.32; PD for Whites = 0.10, 
95%CI: -0.07, 0.27).  Overall the CYP1A1*2A polymorphism did not appear to be associated 
with fibroids in African Americans or Whites.  Main effects for both CYP1B1 polymorphisms 
were close to the null value.  Adjusting for additional covariates (age, BMI, oral contraceptive 
use, births after age 24, smoking status, and number of drinks per week) did not alter prevalence 
ratios by 10% or more, therefore these potential confounders were not included in final models.  
There was no clear evidence of effect measure modification by smoking status, age, alcohol use 
or BMI in combination with any of the genotypes examined.  Observed joint effects did not 
deviate from expected effects on the additive nor multiplicative scales.
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C. Strengths and Limitations
To our knowledge, this is the first study to examine relations between uterine fibroids and 
polymorphisms of CYP1A1 and CYP1B1.  One other study examined the relation between the 
COMT Val158Met polymorphism and fibroids and reported a positive association with the high 
activity Val/Val genotype (OR=2.5; 95% CI: 1.02, 6.15)12.  Although we found a similar 
direction of effect as Al-Hendy’s study, the magnitude of effect estimate was not as strong in our 
study population, which was larger in size.  In addition, we used different methods to ascertain 
fibroid status (ultrasonography versus hysterectomy for symptomatic fibroids) and for estimating 
associations (prevalence ratios versus odds ratios).
Null findings for the two CYP1B1 variants and the COMT variant do not rule out a relation 
between these genes and uterine fibroids. In addition, associations that were observed between 
fibroids and CYP1A1 variants may have resulted from linkage disequilibrium between the 
measured SNP and one or more unmeasured variants, rather than from a direct causal effect of 
the SNP that was evaluated; this is particularly likely for the association observed between 
fibroids in African American women and the CYP1A1*3 variant, which is located in an intronic 
region of the gene. More importantly, the potential for non-causal associations due to chance or 
bias cannot be ruled out, and positive findings for CYP1A1 variants should be interpreted with 
caution given that this is the first study to evaluate these relations. We evaluated only a subset of 
variants in the genes examined, and effects of a single polymorphism, even if functional, might 
not be strong enough to influence the net effect of estrogen metabolism.  We inferred haplotypes 
and evaluated their associations with fibroids to strengthen our ability to capture other 
unmeasured variants in the gene which may be important; however, the SNPs used to define 
these haplotypes covered the gene only sparsely, and we had limited power to evaluate 
associations with uncommon SNPs or haplotypes. We also had limited power to examine 
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modification of SNP main effects by smoking, age, BMI, number of births after age 24, alcohol 
and oral contraception use. Genotyping data were not complete, but the majority of eligible 
women in the parent study had DNA available (75%). There were no clear differences between 
the analysis group and the total study population with respect to all variables.  
Our study design is cross-sectional.  We therefore cannot distinguish between incident and 
prevalent fibroids.  The examination of incident fibroids would help to ascertain temporality; 
however this is not an issue since we are evaluating the effects of genotypes.  Moreover, since 
most fibroids are asymptomatic, it would be logistically difficult to detect incident fibroids.  It 
would require multiple ultrasound examinations beginning at the age of menarche. 
The Uterine Fibroid Study improved upon previous fibroid research (including the study of 
COMT by Al-Hendy et al.) by using ultrasound examinations to identify fibroids, thereby greatly 
increasing the sensitivity with which fibroids status was determined. Because fibroids are highly 
prevalent, we estimated prevalence ratios instead of odds ratios (which overestimate relative risks 
for common outcomes13,14) and used prevalence difference estimates to assess the potential public 
health impact of gene variants on fibroids. We also used MALDI-TOF, a high throughput and 
accurate technique that simultaneously performs multiple genotyping analysis on very small 
quantities of DNA, to genotype DNA15. MALDI-TOF assays used to identify SNPs were reliable 
on repeat assays (>90% concordance for all SNPs).  PHASE was used to infer haplotypes, which 
has been found to be similar16, 17 or slightly superior to other haplotying programs.  This program 
allowed us to reduce random variation error by restricting analysis to haplotype probabilities 
90%18.
All estimates were stratified by race due to the strong associations between race and fibroids, 
and between race and the gene variants examined; however, we did not note evidence of 
substantial variation in associations between gene variants and fibroids between African 
Americans and Whites. The study included a large number of African Americans, which 
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strengthened our ability to evaluate genetic variation as a cause of racial disparities in fibroid 
prevalence and morbidity.  However, race is a proxy measure of a variety of social and 
behavioral factors that may be relevant to fibroid pathogenesis, as well as a crude measure of 
biologic ancestry.
D. Future directions
This study provides evidence supporting the hypothesis that CYP1A1*2C, CYP1A1*3, and 
CYP1A1*4 polymorphisms are related to fibroids, but these findings must be confirmed in other 
study populations.  Future research should examine the functional significance of these 
polymorphisms with regard to estrogen metabolism and fibroid pathogenesis, in addition to 
evaluating other candidate genes. Null findings for COMT and CYP1B1 variants do not rule out a 
role of these genes, and a larger more comprehensive study is needed to fully assess variability 
within CYP1A1, CYP1B1 and COMT genes, with sufficient numbers of African Americans and 
Whites to explore determinants of racial differences in fibroids.  In addition, several genes 
pertinent to estrogen metabolism’s pathway should be considered simultaneously to determine 
the net effect of estrogen metabolism gene polymorphisms on fibroid pathogenesis.  
Although our findings provide no immediate public health benefit, they do provide additional 
evidence for the importance of estrogen in fibroid development.  The associations with CYP1A1 
variants document a need for molecular research to determine the functional significance of each.  
This is especially warranted for CYP1A1*3 polymorphism, since African Americans are the 
predominant carriers of the variant allele and are disproportionately affected by uterine fibroids.  
If the functional significance of all of these SNPs are uncovered, we can do additional studies 
examining modifiable risk factors that increase the risk of prevalent fibroids in the presence of 
these genotypes.
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Table A.1.  Description of CYP1A1, CYP1B1, and COMT polymorphisms evaluated in the 
National Institute of Environmental Health Sciences’ Uterine Fibroid Study 
Polymorphism Alternate 
Name
Location Nucleotide 
Change
Amino Acid Change
CYP1A1
CYP1A1*2A CYP1A1m1 3’ non-
coding 
region
T—C None
CYP1A1*2C CYP1A1m2 exon 7 A—G Isoleucine to Valine
CYP1A1*3 CYP1A1m3 3’ non-
coding 
region
T—C None
CYP1A1*4 CYP1A1m4 exon 7 C—A Threonine to Asparagine
CYP1B1
Leu432Val None exon 3 G—C Leucine to Valine
Ala119Ser None exon 2 G—T Alanine to Serine
COMT
      Val158Met None exon 4 G—A Valine to Methionine
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Table A.2:  Relevant association studies of CYP1A1, CYP1B1, and COMT variants 
Author 
(Year)
Study 
Design
Population Variant(s) Findings
Al- Hendy et 
al 2006
Case-
control
186 cases, 142 
controls
COMT 
Val158Met
Increased risk of fibroids 
among women with 
Val/Val genotype 
(OR=2.5; 95%CI: 1.02, 
6.15)
Ambrosone 
et al 1995
Case-
control
265 female cases, 322 
female controls; all 
Caucasian
CYP1A1*2C Increased risk of breast 
cancer among women 
with CYP1A1*2C variant 
(OR=1.61; 95% CI 0.94-
2.75).  Risk highest among 
those who smoked up to 
29 pack-years (OR=5.22;  
95% CI 1.16-23.56)
Bailey et al 
(1998b)
Case-
control
223 female cases; 221 
female controls; 27% 
African American
CYP1A1*2A, 
CYP1A1*2C, 
CYP1A1*3, 
CYP1A1*4
No association of any 
CYP1A1 variants with 
breast cancer
Cascorbi et 
al. (1996)
Case-
control
157 cases, 314 
controls; Caucasian 
males and females
CYP1A1*4 No association of 
CYP1A1*4 with lung 
cancer
De Vivo et 
al. (2002)
Case-
control
453 female cases, 456 
female controls; 99% 
Caucasian
CYP1B1 
Val432Leu
No association of
Val432Leu with breast 
cancer
Drakoulis et 
al 1994
Case-
control
142 cases, 171 
controls; all German
CYP1A1*2A, 
CYP1A1*2C
No association of 
CYP1A1*2A with lung 
cancer; CYP1A1*2C 
associated with lung 
cancer (OR=2.16, 95% CI 
0.96-5.11)
Fritsche et 
al. (1999)
Case-
control
187 cases, 101 
controls; all Germans
Leu432Val Association of Leu432Val 
with colorectal cancer 
(OR=1.93; 95% CI 1.15-
3.24)
Goodman et 
al. (2001)
Case-
control
129 cases, 144 
controls; 45% were 
Asian, 28% 
Caucasian, 27% Other 
Leu432Val Association of Leu432Val 
with ovarian cancer 
(OR=3.85; 95% CI 1.2-
11.4)
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Author 
(Year)
Study 
Design
Population Variant(s) Findings
Goth-
Goldstein et 
al. (2000)
Case-
control
27 cases, 32 controls 
(race unknown)
CYP1A1*2A No association of 
CYP1A1*2A with breast 
cancer 
Hirvonen et 
al (1992)
Case-
control
106 cases, 122 
controls; Finnish 
population
CYP1A1*2A No association of 
CYP1A1*2A with lung 
cancer
Huang et al 
(1999)
Case-
control
150 cases, 150 
controls
COMT
Val158Met
Increase risk in breast 
cancer among women 
with 2 variant alleles 
compared to women with 
one or less variant alleles
Ishibe et al 
1998
Case-
control
466 female cases, 466 
female controls; >97% 
Caucasian
CYP1A1*2A Increase in breast cancer 
risk among women with 
CYP1A1*2A variant and 
who smoked before age 18 
(RR=5.65; 95% CI, 1.11-
11.7)
Laden et al. 
(2002)
Case-
control
367 female cases, 367 
female controls
CYP1A1*2C Increased in breast cancer 
risk among women with 
CYP1A1*2C variant and 
who had PCB levels in the 
highest category
Lavigne et 
al. (1997)
Case-
control
112 cases, 112 
controls
COMT 
Val158Met
Increased risk in breast 
cancer among 
postmenopausal women 
with 2 variant alleles; 
inverse association among 
premenopausal women 
with 2 variant alleles
Mitrunen et 
al (2001)
Case-
control
483 cases, 482 
controls, Finnish
COMT
Val158Met
Decrease risk in breast 
cancer among 
postmenopausal women 
with 2 alleles and low 
body mass index 
(OR=0.33; 95% CI 0.13-
0.83); increase in risk for 
postmenopausal women 
with 2 alleles and long 
term estrogen use 
(OR=4.02; 95% CI 1.13-
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Author 
(Year)
Study 
Design
Population Variant(s) Findings
14.30), and one variant 
allele and early age at 
menarche (OR=8.59; 95% 
CI 1.85-39.80)
Nakachi et 
al 1991
Case-
control
CYP1A1*2A Increased risk of lung 
cancer among those with 
CYP1A1*2A (OR=7.31; 
95% CI 2.13-25.12)
Rebbeck et 
al. (1994)
Case-
control
96 female cases, 146 
female controls; 
Caucasians
CYP1A1*2C No association of 
CYP1A1*2C with breast 
cancer
Taioli et al 
1995
Case-
control
49 female cases, 256 
female controls;  33% 
African American, 
67% Caucasian 
CYP1A1*2A, 
CYP1A1*3
Increased association with 
breast cancer among 
African American women 
with CYP1A1*2A variant 
(OR=9.7; 95% CI 2.0-
47.9);  No association 
found among Caucasians;  
No association found with 
the CYP1A1*3 variant
Tang et al. 
(2000)
Case-
control
189 male cases, 147 
male controls; all 
Caucasian
CYP1B1
Leu432Val
Leu432Val associated 
with increased prostate 
cancer risk (OR=3.3; 95% 
CI 1.9-9.0)
Tefre et al 
1991
Case-
control
221 cases, 212 
controls; all 
Norwegian
CYP1A1*2A No association found 
between CYP1A1*2A and 
lung cancer
Thompson 
et al (1998)
Cohort 570 women COMT
Val158Met
Increased risk of breast 
cancer in premenopausal 
women with 2 variant 
alleles; inverse 
relationship in 
postmenopausal women
Watanabe et 
al. (2000)
Case-
control
339 female cases, 361 
female controls; all 
Japanese
CYP1B1
Leu432Val, 
Ala119Ser
Leu432Val not associated 
with increased risk of 
breast cancer; Ala119Ser 
associated with both 
breast and lung cancers
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Author 
(Year)
Study 
Design
Population Variant(s) Findings
Zheng et al. 
(2000)
Case-
control
186 female cases, 200 
female controls; all 
Chinese
CYP1B1
Leu432Val
Leu432Val associated 
with increased risk of 
breast cancer (OR=2.3; 
95% CI 1.2–4.5)
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Table A.3.  Distribution of outcome and exposure variables by race among premenopausal 
participants in the National Institute of Environmental Health Sciences Uterine Fibroid Study                            
Variable African 
Americans 
Caucasians Other
Total 583 404 77
Fibroid present (%) 421 (72.21) 201 (49.75) 43 (55.84)
Fibroid size (%)
No fibroids
Fibroid < 2cm
Fibroid 2-3.999cm
Fibroid > 4cm
Missing
155 (26.59)
94 (16.12)
187 (32.08)
140 (24.01)
    7 (1.20)
195 (49.24)
70 (17.68)
87 (21.97)
44 (11.11)
8 (1.98)
32 (42.67)
13 (17.33)
19 (25.33)
11 (14.67)
2 (2.60)
BMI (%)
Normal (<25)
Overweight (25 – 29.9)
Obese (>30)
148 (25.39)
179 (30.70)
256 (43.91)
237 (58.66)
95 (23.51)
72 (17.82)
35 (45.45)
19 (24.68)
23 (29.87)
Age (%)
35-39
40-44
45 and over
220 (37.74)
206 (35.33)
157 (26.93)
137 (33.91)
136 (33.66)
131 (32.43)
29 (37.66)
25 (32.47)
23 (29.87)
Mean number of alcoholic 
drinks/week (%)
   Less than 0.5
   0.5 – 2
   3 – 6
   7 or more
   Missing
300 (51.46)
122 (20.93)
65 (11.15)
58 (9.95)
38 (6.52)
60 (14.85)
115 (28.47)
102 (25.25)
98 (24.26)
29 (7.18)
0 (0)
0 (0)
0 (0)
0 (0)
77 (0)
Oral Contraception Use (%) 535 (91.77) 335 (82.92) 60 (77.92)
Births after age 24 (%)
   0
   1
   2
   3 or more
296 (50.77)
181 (31.05)
85 (14.58)
21 (3.60)
257 (63.61)
57 (14.11)
80 (19.80)
10 (2.48)
43 (55.84)
21 (27.27)
10 (12.99)
3 (3.90)
Smoking Status (%)
Never smoker
Former smoker
Smoker
Missing
277 (47.51)
134 (22.98)
168 (28.82)
4 (0.69)
234 (57.92)
139 (34.41)
31 (7.67)
0 (0)
47 (61.04)
18 (23.38)
12 (15.58)
0 (0)
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Variable African 
Americans 
Caucasians Other
CYP1A1*2A (%)
Wildtype
Heterozygous
Homozygous Variant 
Missing
354 (60.72)
204 (34.99)
23 (3.95)
2 (0.34)
305 (75.50)
89 (22.03)
9 (2.23)
1 (0.25)
38 (49.35)
27 (35.06)
12 (15.58)
0 (0)
CYP1A1*2C (%)
Wildtype
Heterozygous
   Homozygous Variant 
   Missing
571 (97.94)
10 (1.72)
0 (0)
2 (0.34)
363 (89.85)
38 (9.41)
1 (0.25)
2 (0.50)
52 (67.53)
18 (23.38)
7 (9.09)
 0 (0)
CYP1A1*3 (%)
Wildtype
Heterozygous
   Homozygous Variant
   Missing 
498 (85.42)
79 (13.55)
4 (0.69)
2 (0.34)
401 (99.26)
2 (0.50)
0 (0)
1 (0.25)
73 (94.81)
4 (5.19)
0 (0)
0 (0)
CYP1A1*4 (%)
Wildtype
Heterozygous
   Homozygous Variant
   Missing
568 (97.43)
13 (2.23)
0 (0)
2 (0.34)
368 (91.09)
36 (8.91)
0 (0)
0 (0)
74 (96.10)
2 (2.60)
1 (1.30)
0 (0)
Ala119Ser (%)
Wildtype
Heterozygous
   Homozygous Variant
   Missing
152 (26.07)
289 (49.57)
136 (23.33)
6 (1.03)
204 (50.50)
171 (42.33)
27 (6.68)
2 (0.50)
38 (49.35)
28 (36.36)
11 (14.29)
0 (0)
Leu432Val (%)
Wildtype
Heterozygous
   Homozygous Variant
   Missing
326 (55.92)
216 (37.05)
39 (6.69)
2 (0.34)
67 (16.58)
205 (50.74)
132 (32.67)
0 (0)
20 (25.97)
31 (40.26)
26 (33.77)
0 (0)
COMT (%)
   Wildtype
   Heterozygous
   Homozygous
   Missing
274 (47.08)
252 (43.30)
56 (9.62)
56 (9.61)
96 (23.76)
202 (50.00)
106 (26.24)
0 (0)
35 (45.45)
29 (37.66)
13 (16.88)
0 (0)
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Table A.4. Examination of Hardy Weinberg Equilibrium among noncases, National Institute of 
Environmental Health Sciences Uterine Fibroid Study
African Americans WhitesGenotypea
Expected 
frequency
Observed 
frequency
2 Expected 
frequency
Observed 
frequency
2
CYP1A1*2A
AA
AB
BB
94.46
53.08
7.46
92
58
5
1.33 144.74
46.52
3.74
145
46
4
0.02
CYP1A1*2C
AA
AB
BB
152.04
2.97
0.01
152
3
0
0.01 172.68
21.64
0.68
172
23
0
0.77
CYP1A1*3
AA
AB
BB
139.41
15.17
0.41
140
14
1
0.93 193
1
0.0012
193
1
0
0.001
CYP1A1*4
AA
AB
BB
153.01
1.99
0.01
153
2
0
0.001 181.25
13.50
0.25
181
14
0
0.27
Ala119Ser
AA
AB
BB
39.26
76.49
37.26
40
75
38
0.06 99.39
78.22
15.39
98
81
14
0.24
Leu432Val
AA
AB
BB
83.85
60.31
10.85
84
60
11
0.004 35.33
95.34
64.33
34
98
63
0.15
COMT
AA
AB
BB
47.2
97.5
50.3
47
98
50
0.01 69.00
69.00
17.00
65
77
13
2.10
a
 AA=Wildtype (p2), AB=Heterzygous (2pq), BB=Homozygous Variant (q2)
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Table A.5.  Primers used during MALDI-TOF procedure to genotype polymorphisms of 
CYP1A1, CYP1B1, and COMT
Polymorphism Forward Primer Reverse Primer Mass Extend Primer
CYP1A1
   CYP1A1*2A ACGTTGGATGGGATAGCCAGGAAGAGAAAG ACGTTGGATGTATCTTTGGCATGGGCAAGC AGCGGAAGTGTATCGGTGAGA
   CYP1A1*2C ACGTTGGATGTATCTTTGGCATGGGCAAGC ACGTTGGATGGGATAGCCAGGAAGAGAAAG AGACCTCCCA
   CYP1A1*3 ACGTTGGATGACTACTCAGAGGCTGAGGTG ACGTTGGATGAGTGCACTGGTACCATTTTG CACTGTAACCTCCACCTCC
   CYP1A1*4 ACGTTGGATGATATGTGCACTCCCTGTGCG ACGTTGGATGCTTCTGGCCTTGTAAGACCC GTAAGACCCTTATTGCTGTCC
CYP1B1
    Ala119Ser ACGTTGGATGTAGTGGTGCTGAATGGCGAG ACGTTGGATGGACACCACACGGAAGGAGG CACGGAAGGAGGCGAAGG
    Leu432Val ACGTTGGATGTCCAAGAATCGAGCTGGATC ACGTTGGATGTTGTCAACCAGTGGTCTGTG GGTCTGTGAATCATGACCCA
COMT
Val158Met ACGTTGGATGACCCAGCGGATGGTGGATTT ACGTTGGATGGCCCTTTTTCCAGGTCTGAC GGCATGCACACCTTGTCCTTCA
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Table A.6: Estimated power to detect main effects
odds ratios (OR) by exposure prevalence ( = .05)
for Whites
ORGene Prevalence 
(Wildtype)
(One or more variant alleles) 1.5 2.0 3.0
CYP1A1*2A
0.7568
0.2432
0.404 0.824 0.994
CYP1A1*2C
0.9030
0.0970
0.216 0.502 0.846
CYP1A1*3
0.9950
0.0050
0.046 0.067 0.102
CYP1A1*4
0.9109
0.0891
0.207 0.480 0.825
CYP1B1  Ala119Ser
0.5075
0.4925
0.522 0.926 1.000
CYP1B1  Leu432Val
0.1658
0.8342
0.331 0.728 0.974
COMT  Val158Met
     0.2376
     0.7624
0.411 0.831 0.994
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Table A.7: Estimated power to detect main effects
odds ratios (OR) by exposure prevalence ( = .05)
for African American
ORGene Prevalence 
(Wildtype)
(One or more variant alleles) 1.5 2.0 3.0
CYP1A1*2A
0.6093
0.3907
0.501 0.902 0.999
CYP1A1*2C
0.9828
0.0172
0.056 0.090 0.149
CYP1A1*3
0.8571
0.1429
0.282 0.635 0.940
CYP1A1*4
0.9776
0.0224
0.066 0.114 0.204
CYP1B1  Ala119Ser
0.2634
0.7366
0.462 0.856 0.994
CYP1B1  Leu432Val
0.5611
0.4389
0.519 0.914 0.999
COMT  Val158Met
     0.4708
     0.5292
0.504 0.899 0.998
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Table A.8. Estimated pairwise linkage disequilibrium (LD) among White premenopausal women 
in Uterine Fibroid Study (using r2) 
CYP1A1*2A CYP1A1*3 CYP1A1*2C
CYP1A1*2A
CYP1A1*3 <0.001
CYP1A1*2C 0.341 <0.001
CYP1A1*4 <0.001 <0.001 0.002
Ala119Ser
Leu432Val 0.239
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Table A.9. Estimated pairwise linkage disequilibrium (LD) among African American 
premenopausal women in Uterine Fibroid Study (using r2) 
CYP1A1*2A CYP1A1*3 CYP1A1*2C
CYP1A1*2A
CYP1A1*3 0.021
CYP1A1*2C 0.022 <0.001
CYP1A1*4 0.003 <0.001 <0.001
Ala119Ser
Leu432Val 0.045
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Table A.10.  Distribution of haplotype and diplotype frequencies among premenopausal African American and White participants in the 
Uterine Fibroid Study
Fibroid Status
African American Caucasian
Genotype
No 
Fibroids
Fibroids 
present
Small Medium Large No 
Fibroids
Fibroids 
present
Small Medium Large
CYP1A1
haplotypesa
N 310 838 186 372 280 390 400 140 172 88
CTAC 65(21.0) 171(20.3) 36(19.1) 75(20.1) 60(21.4) 31(7.9) 35(8.7) 15(10.7) 14(8.0) 6(6.8)
CTGC 3(1.0) 6(0.7) 1(0.5) 2(0.5) 3(1.1) 23(5.9) 17(4.2) 3(2.1) 10(5.7) 4(4.5)
TCAC 16(5.2) 70(8.3) 14(7.4) 31(8.3) 25(8.9) 1(0.3) 1(0.2) 0(0.0) 0(0.0) 1(1.1)
TTAA 2(0.6) 11(1.3) 1(0.5) 3(0.8) 7(2.5) 14(3.6) 20(5.0) 6(4.3) 11(6.3) 3(3.4)
TTAC 224(72.3) 579(68.8) 134(71.3) 260(69.5) 185(66.1) 321(82.3) 327(81.3) 116(82.9) 137(78.7) 74(84.1)
TTGC 0(0.0) 1(0.1) 0(0.0) 1(0.3) 0(0.0) 0 0 0 0 0
CYP1A1
diplotypesa
N 155 419 93 186 140 195 201 70 86 44
CTAC/CTAC 5(3.2) 17(4.0) 4(4.3) 6(3.2) 7(5.0) 2(1.0) 1(0.5) 0(0.0) 1(1.1) 0(0.0)
CTAC/CTGC 0(0.0) 1(0.2) 1(1.1) 0(0.0) 0(0.0) 2(1.0) 3(1.5) 0(0.0) 2(2.3) 1(2.3)
CTGC/CTGC 0 0 0 0 0 0(0.0) 1(0.5) 0(0.0) 1(1.1) 0(0.0)
TCAC/CTAC 2(1.3) 17(4.0) 5(5.3) 7(3.7) 5(3.6) 0(0.0) 1(0.5) 0(0.0) 0(0.0) 1(2.3)
TCAC/TCAC 1(0.6) 3(0.7) 0(0.0) 2(1.1) 1(0.7) 0 0 0 0 0
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Fibroid Status
African American Caucasian
Genotype
No 
Fibroids
Fibroids 
present
Small Medium Large No 
Fibroids
Fibroids 
present
Small Medium Large
TTAA/CTAC 1(0.6) 1(0.2) 0(0.0) 0(0.0) 1(0.7) 25(12.8) 29(14.4) 15(21.4) 10(11.5) 4(9.1)
TTAA/TCAC 0(0.0) 1(0.2) 0(0.0) 0(0.0) 1(0.7) 0 0 0 0 0
TTAC/CTAC 52(33.5) 118(28.0) 22(23.4) 56(29.9) 40(28.6) 0 0 0 0 0
TTAC/CTGC 3(1.9) 5(1.2) 0(0.0) 2(1.1) 3(2.1) 21(10.8) 12(6.0) 3(4.3) 6(6.9) 3(6.8)
TTAC/TCAC 12(7.7) 46(10.9) 9(9.6) 20(10.7) 17(12.1) 1(0.5) 1(0.5) 0(0.0) 0(0.0) 1(2.3)
TTAC/TTAA 1(0.6) 9(2.1) 1(1.1) 3(1.6) 5(3.6) 14(7.2) 19(9.5) 6(8.6) 11(12.6) 2(4.5)
TTAC/TTAC 78(50.3) 200(47.5) 51(54.3) 89(47.6) 60(42.9) 130(66.7) 133(66.2) 46(65.7) 55(63.2) 32(72.7)
TTAC/TTGC 0(0.0) 1(0.2) 0(0.0) 1(0.5) 0(0.0) 0 0 0 0 0
CYP1B1 
haplotypesb
N 240 678 146 302 230 386 402 140 174 88
GC 16(5.2) 49(5.8) 7(3.7) 22(5.9) 20(7.1) 115(29.5) 126(31.3) 47(33.6) 55(31.6) 24(27.3)
GG 106(34.2) 302(35.9) 66(35.1) 133(35.6) 103(36.8) 162(41.5) 164(40.8) 55(39.3) 70(40.2) 39(44.3)
TC 32(10.3) 80(9.5) 21(11.2) 33(8.8) 26(9.3) 106(27.2) 110(27.4) 38(27.1) 49(28.2) 23(26.1)
TG 86(27.7) 247(29.3) 52(27.7) 114(30.5) 81(28.9) 3(0.8) 2(0.5) 0(0.0) 0(0.0) 2(2.3)
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Fibroid Status
African American Caucasian
Genotype
No 
Fibroids
Fibroids 
present
Small Medium Large No 
Fibroids
Fibroids 
present
Small Medium Large
CYP1B1
diplotypesb
N 120 339 73 170 115 193 201 70 87 44
GC/GC 2(1.3) 3(0.7) 0(0.0) 0(0.0) 3(2.1) 15(7.7) 17(8.5) 7(10.0) 8(9.2) 2(4.5)
GC/TC 3(1.9) 12(2.9) 3(3.2) 4(2.1) 5(3.6) 33(16.9) 38(18.9) 13(18.6) 18(20.7) 7(15.9)
GG/GC 9(5.8) 31(7.4) 4(4.3) 18(9.6) 9(6.4) 52(26.7) 54(26.9) 20(28.6) 21(24.1) 13(29.5)
GG/GG 29(18.7) 75(17.8) 20(21.3) 28(15.0) 27(19.3) 31(15.9) 31(15.4) 11(15.7) 14(16.1) 6(13.6)
GG/TC 0 0 0 0 0 45(23.1) 47(23.4) 13(18.6) 21(24.1) 13(29.5)
GG/TG 39(25.2) 121(28.7) 22(23.4) 59(31.6) 40(28.6) 3(1.5) 1(0.5) 0(0.0) 0(0.0) 1(2.3)
TC/TC 6(3.9) 11(2.6) 3(3.2) 4(2.1) 4(2.9) 14(7.2) 12(6.0) 6(8.6) 5(5.7) 1(2.3)
TG/TC 17(11.0) 46(10.9) 12(12.8) 21(11.2) 13(9.3) 0(0.0) 1(0.5) 0(0.0) 0(0.0) 1(2.3)
TG/TG 15(9.7) 40(9.5) 9(9.6) 17(9.1) 14(10.0) 0 0 0 0 0
aOrder of SNPs:  CYP1A1*2A, CYP1A1*3, CYP1A1*2C, CYP1A1*4
bOrder of SNPs:  CYP1B1 Ala119Ser, CYP1B1 Leu432Val
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Table A.11. Assessment of confounding for the main effects of COMT allele and presence of fibroids 
among premenopausal African American and White women in the Uterine Fibroid Study
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
COMT 0.92 ( 0.84,  1.02 )
COMT, Age 0.91 ( 0.83,  1.00 )
COMT, BMI 0.93 ( 0.85,  1.03 )
COMT, Smoking 0.92 ( 0.83,  1.02 )
COMT, Oral conceptive use 0.93 ( 0.84,  1.03 )
COMT, Full term births after age 24 0.93 ( 0.84,  1.03 )
COMT, Alcohol use 0.94 ( 0.85,  1.04 )
Full Modela 0.97 ( 0.88,  1.07 )
Whites
COMT 1.02 ( 0.81,  1.28 )
COMT, Age 1.02 ( 0.83,  1.27 )
COMT, BMI 1.02 ( 0.81,  1.28 )
COMT, Smoking 1.01 ( 0.80,  1.28 )
COMT, Oral conceptive use 1.02 ( 0.81,  1.28 )
COMT, Full term births after age 24 1.01 ( 0.81,  1.27 )
COMT, Full term (full25pc) 1.01 ( 0.80,  1.27 )
COMT, Alcohol use 1.03 ( 0.81,  1.31 )
Full Modela 1.03 ( 0.82,  1.28 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI, 
oral contraceptive use, and alcohol use
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Table A.12. Assessment of confounding for the main effects of COMT allele and presence of largest fibroids  2cm 
among African American and White premenopausal women in the the Uterine Fibroid Study
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
COMT 0.74 ( 0.54,  1.03 )
COMT, Age 0.72 ( 0.53,  0.99 )
COMT, BMI 0.77 ( 0.56,  1.05 )
COMT, Smoking 0.73 ( 0.53,  1.00 )
COMT, Oral conceptive use 0.76 ( 0.55,  1.05 )
COMT, Full term births after age 24 0.75 ( 0.54,  1.03 )
COMT, Alcohol use 0.78 ( 0.57,  1.08 )
Full Modela 0.80 ( 0.59,  1.09 )
Whites
COMT 1.17 ( 0.72,  1.99 )
COMT, Age 1.16 ( 0.71,  1.89 )
COMT, BMI 1.19 ( 0.72,  1.97 )
COMT, Smoking 1.21 ( 0.72,  2.01 )
COMT, Oral conceptive use 1.21 ( 0.72,  2.02 )
COMT, Full term births after age 24 1.19 ( 0.72,  1.99 )
COMT, Alcohol use 1.13 ( 0.68,  1.88 )
Full Modelb 1.12 ( 1.65,  2.02 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI, 
oral contraceptive use, and alcohol use
b
 Full model includes the following variables: COMT genotype, age, smoking, BMI, oral contraceptive 
use, and alcohol use
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Table A.13 Assessment of confounding for the main effects of COMT allele and presence of largest fibroids >2cm 4 
among African American and White premenopausal women in the Uterine Fibroid Study
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
COMT 0.92 ( 0.76,  1.12 )
COMT, Age 0.90 ( 0.75,  1.09 )
COMT, BMI 0.94 ( 0.78,  1.13 )
COMT, Smoking 0.91 ( 0.75,  1.10 )
COMT, Oral conceptive use 0.93 ( 0.77,  1.13 )
COMT, Full term 0.92 ( 0.76,  1.11 )
COMT, Full term births after age 24 0.93 ( 0.77,  1.13 )
COMT, Alcohol use 0.97 ( 0.79,  1.19 )
Full Model a 0.99 ( 0.82,  1.20 )
Whites
COMT 0.92 ( 0.62,  1.36 )
COMT, Age 0.95 ( 0.65,  1.38 )
COMT, BMI 0.92 ( 0.62,  1.36 )
COMT, Smoking 0.90 ( 0.61,  1.34 )
COMT, Oral conceptive use 0.91 ( 0.61,  1.35 )
COMT, Full term 0.91 ( 0.62,  1.35 )
COMT, Full term births after age 24 0.94 ( 0.63,  1.40 )
COMT, Alcohol use 0.95 ( 0.62,  1.44 )
Full Model b 0.95 ( 0.64,  1.42 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI, oral 
contraceptive use, and alcohol use
b
 Full model includes the following variables: COMT genotype, age, smoking, BMI, oral contraceptive use, 
and alcohol use
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Table A.14 Assessment of confounding for the main effects of COMT allele and presence of largest fibroids >4 
among African American and White premenopausal women in the Uterine Fibroid Study
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
COMT 0.84 ( 0.66,  1.07 )
COMT, Age 0.82 ( 0.66,  1.01 )
COMT, BMI 0.85 ( 0.67,  1.08 )
COMT, Smoking 0.85 ( 0.67,  1.09 )
COMT, Oral conceptive use 0.85 ( 0.67,  1.08 )
COMT, Births after age 24 0.85 ( 0.67,  1.09 )
COMT, Alcohol use 0.86 ( 0.67,  1.11 )
Full Modela 0.89 ( 0.71,  1.12 )
Whites
COMT 1.06 ( 0.56,  2.02 )
COMT, Age 1.08 ( 0.58,  2.03 )
COMT, BMI 1.06 ( 0.56,  2.00 )
COMT, Smoking 1.04 ( 0.55,  1.98 )
COMT, Oral conceptive use 1.05 ( 0.55,  1.99 )
COMT, Full term births after age 24 1.02 ( 0.55,  1.92 )
COMT, Alcohol use 1.10 ( 0.56,  2.16 )
Full Modelb 1.07 ( 0.54,  2.01 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI, oral 
contraceptive use, and alcohol use
b
 Full model includes the following variables: COMT genotype, age, smoking, BMI, oral contraceptive use, 
and alcohol use
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Table A.15 Prevalence Ratio (PR) and 95% Confidence interval (CI) for the association between fibroid presence and 
interactions of COMT genotype and participant characteristics among premenopausal African Americans, Uterine 
Fibroid Study
Wt/Wt Wt/Var & Var/Var
Characteristics N (%) PR (95% CI) N (%) PR (95% CI)
Total 274(.) 308(.)
Ag e
35-39 106(38.7) 1.0 114(37.0) 0.87 ( 0.71,  1.06)
40-44 97(35.4) 1.07 ( 0.90,  1.28) 109(35.4) 1.18 ( 0.91,  1.52)
>=45 71(25.9) 1.31 ( 1.13,  1.53) 85(27.6) 1.01 ( 0.79,  1.28)
BMI
Normal 63(23.0) 1.0 84(27.3) 0.90 ( 0.71,  1.14)
Overweight 85(31.0) 1.13 ( 0.92,  1.39) 94(30.5) 1.03 ( 0.77,  1.39)
Obese 126(46.0) 1.16 ( 0.96,  1.40) 130(42.2) 1.05 ( 0.80,  1.39)
Smoking Status
Never Smoked
132(48.2) 1.0 145(47.1) 0.99 ( 0.85,  1.15)
Past Smoker 59(21.5) 1.09 ( 0.91,  1.29) 74(24.0) 0.96 ( 0.75,  1.23)
Current Smoker 82(29.9) 1.13 ( 0.97,  1.32) 86(27.9) 0.82 ( 0.64,  1.04)
Oral Contraceptive Use
Never Used OC 16(5.8) 1.0 32(10.4) 0.95 ( 0.59,  1.53)
Current/Past User Of OC 258(94.2) 1.23 ( 0.84,  1.81) 276(89.6) 0.98 ( 0.60,  1.60)
Number Of Full term Births
None 144(52.6) 1.0 152(49.4) 0.91 ( 0.80,  1.04)
1 83(30.3) 0.94 ( 0.81,  1.09) 97(31.5) 0.99 ( 0.79,  1.24)
2 40(14.6) 0.85 ( 0.67,  1.07) 45(14.6) 1.21 ( 0.90,  1.65)
3 Or More 7(2.6) 0.90 ( 0.56,  1.45) 14(4.5) 0.77 ( 0.37,  1.56)
Number Of Alcoholic Drinks per 
week
Less Than 0.5 151(55.1) 1.0 148(48.1) 0.96 ( 0.84,  1.10)
0.5-2 51(18.6) 0.92 ( 0.75,  1.13) 71(23.1) 1.00 ( 0.76,  1.32)
3-6 22(8.0) 1.14 ( 0.94,  1.38) 43(14.0) 0.83 ( 0.62,  1.12)
7 Or More 32(11.7) 1.03 ( 0.84,  1.26) 26(8.4) 1.12 ( 0.84,  1.49)
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Table A.16 Prevalence Ratio (PR) and 95% Confidence interval (CI) for the association between fibroid presence and interactions 
of COMT genotype and participant characteristics among Whites, National Institute of Environmental Health Science Uterine 
Fibroid Study
WT/Wt Wt/Var & Var/Var
Characteristics N (%) PR (95% CI) N (%) PR (95% CI)
Total 96(.) 308(.)
Age
35-39 29(30.2) 1.0 108(35.1) 0.82 ( 0.49,  1.35)
40-44 36(37.5) 0.91 ( 0.50,  1.64) 100(32.5) 1.54 ( 0.78,  3.04)
>=45 31(32.3) 1.63 ( 1.00,  2.66) 100(32.5) 1.22 ( 0.69,  2.16)
BMI
Normal 56(58.3) 1.0 181(58.8) 1.03 ( 0.75,  1.41)
Overweight 22(22.9) 0.94 ( 0.55,  1.61) 73(23.7) 1.05 ( 0.58,  1.92)
Obese 18(18.8) 1.27 ( 0.80,  2.01) 54(17.5) 0.91 ( 0.53,  1.56)
Smoking Status
Never Smoked 61(63.5) 1.0 173(56.2) 1.02 ( 0.75,  1.37)
Past Smoker 29(30.2) 0.98 ( 0.62,  1.55) 110(35.7) 1.05 ( 0.63,  1.75)
Current Smoker 6(6.3) 1.36 ( 0.73,  2.53) 25(8.1) 0.83 ( 0.40,  1.71)
Oral Contraceptive Use
Never Used OC 12(12.5) 1.0 57(18.5) 0.87 ( 0.51,  1.50)
Current/Past User Of OC 84(87.5) 0.84 ( 0.49,  1.42) 251(81.5) 1.20 ( 0.66,  2.18)
Number Of Full term Births 
None 59(61.5) 1.0 198(64.3) 0.94 ( 0.74,  1.20)
1 19(19.8) 0.55 ( 0.73,  1.10) 38(12.3) 1.55 ( 0.70, 3.42)
2 or more 18(18.7) 0.77 ( 0.44,  1.35) 72 (23.4) 1.06 ( 0.57,  2.00)
Number Of Alcoholic Drinks per week
 Less Than 0.5 16(16.7) 1.0 44(14.3) 0.77 ( 0.42,  1.43)
0.5-2 23(24.0) 0.96 ( 0.50,  1.83) 92(29.9) 1.35 ( 0.62,  2.94)
3-6 26(27.1) 0.80 ( 0.40,  1.59) 76(24.7) 1.97 ( 0.88,  4.39)
7 Or More 24(25.0) 1.22 ( 0.68,  2.19) 74(24.0) 1.03 ( 0.49,  2.16)
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Table A.17 Assessment of confounding for the main effects of COMT allele and presence of fibroids among African 
American and White premenopausal women in the Uterine Fibroid Study
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1A1*2A 0.97 ( 0.87,  1.08 )
CYP1A1*2A, Age 0.98 ( 0.89,  1.08 )
CYP1A1*2A, BMI 0.99 ( 0.89,  1.10 )
CYP1A1*2A, Smoking 0.97 ( 0.88,  1.08 )
CYP1A1*2A, Oral conceptive use 0.98 ( 0.88,  1.08 )
CYP1A1*2A, Full term births after age 24 0.98 ( 0.88,  1.09 )
CYP1A1*2A, Alcohol use 0.96 ( 0.86,  1.07 )
Full Modela 1.01 ( 0.91,  1.12 )
Whites
CYP1A1*2A 0.94 ( 0.75,  1.19 )
CYP1A1*2A, Age 0.98 ( 0.79,  1.21 )
CYP1A1*2A, BMI 0.93 ( 0.74,  1.18 )
CYP1A1*2A, Smoking 0.93 ( 0.74,  1.18 )
CYP1A1*2A, Oral conceptive use 0.94 ( 0.75,  1.19 )
CYP1A1*2A, Full term births after age 24 0.95 ( 0.76,  1.20 )
CYP1A1*2A, Alcohol use 0.92 ( 0.71,  1.18 )
Full Modela 0.93 ( 0.74,  1.17 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI, oral 
contraceptive use, and alcohol use
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Table A.18 Assessment of confounding for the main effects of CYP1A1*3 allele and presence of fibroids among 
African American and White premenopausal women in the Uterine Fibroid Study
Variables in model
 Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1A1*3 1.15 ( 1.02,  1.29 )
CYP1A1*3, Age 1.16 ( 1.06,  1.28 )
CYP1A1*3, BMI 1.13 ( 1.00,  1.26 )
CYP1A1*3, Smoking 1.14 ( 1.01,  1.28 )
CYP1A1*3, Oral conceptive use 1.13 ( 1.01,  1.27 )
CYP1A1*3, Full term 1.16 ( 1.03,  1.30 )
CYP1A1*3, Full term births after age 24 1.15 ( 1.02,  1.29 )
CYP1A1*3, Alcohol use 1.15 ( 1.02,  1.29 )
Full Modela 1.08 ( 0.97,  1.20 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI, oral 
contraceptive use, and alcohol use
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Table A.19 Assessment of confounding for the main effects of CYP1A1*2C allele and presence of fibroids among 
African American and White premenopausal women in the Uterine Fibroid Study
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African  Americans
CYP1A1*2C 0.96 ( 0.64,  1.45 )
CYP1A1*2C, Age 0.95 ( 0.65,  1.39 )
CYP1A1*2C, BMI 0.91 ( 0.60,  1.37 )
CYP1A1*2C, Smoking 0.97 ( 0.65,  1.47 )
CYP1A1*2C, Oral conceptive use 0.99 ( 0.67,  1.48 )
CYP1A1*2C, Full term 24 0.97 ( 0.65,  1.46 )
CYP1A1*2C, Full term births after age 0.96 ( 0.64,  1.45 )
CYP1A1*2C, Alcohol use 0.96 ( 0.64,  1.44 )
Full Modela 0.97 ( 0.61,  1.54 )
Whites
CYP1A1*2C 0.80 ( 0.54,  1.17 )
CYP1A1*2C, Age 0.82 ( 0.57,  1.18 )
CYP1A1*2C, BMI 0.79 ( 0.53,  1.16 )
CYP1A1*2C, Smoking 0.79 ( 0.53,  1.16 )
CYP1A1*2C, Oral conceptive use 0.80 ( 0.54,  1.18 )
CYP1A1*2C, Full term births after age 24 0.82 ( 0.56,  1.21 )
CYP1A1*2C, Alcohol use 0.69 ( 0.43,  1.10 )
Full Modela 0.73 ( 0.46,  1.13 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI, oral 
contraceptive use, and alcohol use
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Table A.20 Assessment of confounding for the main effects of CYP1A1*4 allele and presence of fibroids among 
African American and White premenopausal women in the Uterine Fibroid Study
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1A1*4 1.16 ( 0.92,  1.48 )
CYP1A1*4, Age 1.05 ( 0.84,  1.33 )
CYP1A1*4, BMI 1.12 ( 0.88,  1.42 )
CYP1A1*4, Smoking 1.18 ( 0.93,  1.50 )
CYP1A1*4, Oral conceptive use 1.15 ( 0.91,  1.46 )
CYP1A1*4, Full term births after age 24 1.15 ( 0.91,  1.46 )
CYP1A1*4, Alcohol use 1.26 ( 1.04,  1.54 )
Full Modela 1.08 ( 0.89,  1.32 )
Whites
CYP1A1*4 1.20 ( 0.90,  1.61 )
CYP1A1*4, Age 1.20 ( 0.94,  1.53 )
CYP1A1*4, BMI 1.18 ( 0.89,  1.58 )
CYP1A1*4, Smoking 1.22 ( 0.91,  1.64 )
CYP1A1*4, Oral conceptive use 1.20 ( 0.90,  1.61 )
CYP1A1*4, Full term births after age 24 1.25 ( 0.94,  1.66 )
CYP1A1*4, Alcohol use 1.26 ( 0.95,  1.68 )
Full Model (full term) 1.26 ( 0.92,  1.72 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI, oral 
contraceptive use, and alcohol use
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Table A.21 Assessment of confounding for the main effects of CYP1B1AS allele and presence of fibroids among 
African American and White premenopausal women in the Uterine Fibroid Study
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1B1AS 1.00 ( 0.90,  1.12 )
CYP1B1AS, Age 1.01 ( 0.91,  1.13 )
CYP1B1AS, BMI 1.02 ( 0.91,  1.14 )
CYP1B1AS, Smoking 1.00 ( 0.89,  1.12 )
CYP1B1AS, Oral conceptive use 1.01 ( 0.90,  1.13 )
CYP1B1AS, Full term births after age 24 1.02 ( 0.91,  1.14 )
CYP1B1AS, Alcohol use 1.02 ( 0.91,  1.15 )
Full Modela 1.07 ( 0.95,  1.20 )
Whites
CYP1B1AS 1.00 ( 0.83,  1.21 )
CYP1B1AS, Age 1.01 ( 0.84,  1.20 )
CYP1B1AS, BMI 0.97 ( 0.80,  1.18 )
CYP1B1AS, Smoking 1.00 ( 0.83,  1.22 )
CYP1B1AS, Oral conceptive use 1.00 ( 0.82,  1.21 )
CYP1B1AS, Full term births after age 24 1.01 ( 0.84,  1.23 )
CYP1B1AS, Alcohol use 0.98 ( 0.80,  1.20 )
Full Modelb 0.98 ( 0.80,  1.20 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI, oral 
contraceptive use, and alcohol use
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Table A.22. Assessment of confounding for the main effects of CYP1B1LV allele and presence of fibroids among 
African American and White premenopausal women in the Uterine Fibroid Study
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1B1LV 0.97 ( 0.88,  1.08 )
CYP1B1LV, Age 1.00 ( 0.91,  1.10 )
CYP1B1LV, BMI 0.98 ( 0.89,  1.09 )
CYP1B1LV, Smoking 0.97 ( 0.87,  1.07 )
CYP1B1LV, Oral conceptive use 0.98 ( 0.88,  1.08 )
CYP1B1LV, Full term births after age 24 0.98 ( 0.89,  1.08 )
CYP1B1LV, Alcohol use 0.98 ( 0.88,  1.09 )
Full Modela 0.99 ( 0.90,  1.09 )
Whites
CYP1B1LV 1.06 ( 0.81,  1.38 )
CYP1B1LV, Age 1.08 ( 0.84,  1.39 )
CYP1B1LV, BMI 1.05 ( 0.80,  1.37 )
CYP1B1LV, Smoking 1.06 ( 0.81,  1.39 )
CYP1B1LV, Oral conceptive use 1.06 ( 0.81,  1.39 )
CYP1B1LV, Full term births after age 24 1.05 ( 0.80,  1.37 )
CYP1B1LV, Alcohol use 1.01 ( 0.77,  1.33 )
Full Model (full term) 1.03 ( 0.80,  1.33 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI, oral 
contraceptive use, and alcohol use
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Table A.23. Assessment of confounding for the main effects of CYP1A1*2A allele and fibroid prevalence among 
African American and White premenopausal women in the Uterine Fibroid Study whose largest fibroid recorded was 
<2cm (small) compared to no fibroids 
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1A1*2A 0.85 ( 0.60,  1.19 )
CYP1A1*2A, Age 0.87 ( 0.62,  1.22 )
CYP1A1*2A, BMI 0.91 ( 0.64,  1.28 )
CYP1A1*2A, Smoking 0.86 ( 0.61,  1.21 )
CYP1A1*2A, Oral conceptive use 0.87 ( 0.62,  1.22 )
CYP1A1*2A, Full term births after age 24 0.86 ( 0.61,  1.22 )
CYP1A1*2A, Alcohol use 0.83 ( 0.59,  1.17 )
Full Modela 0.95 ( 0.68,  1.33 )
Whites
CYP1A1*2A 1.00 ( 0.63,  1.59 )
CYP1A1*2A, Age 1.04 ( 0.67,  1.59 )
CYP1A1*2A, BMI 0.97 ( 0.61,  1.53 )
CYP1A1*2A, Smoking 1.02 ( 0.64,  1.62 )
CYP1A1*2A, Oral conceptive use 1.01 ( 0.63,  1.59 )
CYP1A1*2A, Full term births after age 24 1.01 ( 0.64,  1.59 )
CYP1A1*2A, Alcohol use 1.10 ( 0.69,  1.74 )
Full Model (full term) 1.07 ( 0.70,  1.64 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI,           
oral contraceptive use, and alcohol use
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Table A.24. Assessment of confounding for the main effects of CYP1A1*3 allele and fibroid prevalence among 
African American and White premenopausal women in the Uterine Fibroid Study whose largest fibroid recorded was 
<2cm (small) compared to no fibroids 
Variables in model
Prevalence 
Ratio PR 95% CI
African Americans
CYP1A1*3 1.35 ( 0.89,  2.05 )
CYP1A1*3, Age 1.44 ( 0.96,  2.16 )
CYP1A1*3, BMI 1.29 ( 0.86,  1.94 )
CYP1A1*3, Smoking 1.36 ( 0.90,  2.07 )
CYP1A1*3, Oral conceptive use 1.31 ( 0.87,  1.99 )
CYP1A1*3, Full term 1.39 ( 0.91,  2.10 )
CYP1A1*3, Full term births after age 24 1.37 ( 0.90,  2.09 )
CYP1A1*3, Alcohol use 1.38 ( 0.92,  2.05 )
Full Modela 1.36 ( 0.93,  2.00 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI, oral 
contraceptive use, and alcohol use
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Table A.25. Assessment of confounding for the main effects of CYP1B1AS allele and fibroid prevalence among 
African American and White premenopausal women in the Uterine Fibroid Study whose largest fibroid recorded was 
<2cm (small) compared to no fibroids
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1B1AS 1.05 ( 0.72,  1.52 )
CYP1B1AS, Age 1.06 ( 0.74,  1.54 )
CYP1B1AS, BMI 1.10 ( 0.76,  1.60 )
CYP1B1AS, Smoking 1.02 ( 0.70,  1.48 )
CYP1B1AS, Oral conceptive use 1.07 ( 0.74,  1.55 )
CYP1B1AS, Full term 1.08 ( 0.74,  1.58 )
CYP1B1AS, Full term births after age 24 1.08 ( 0.74,  1.57 )
CYP1B1AS, Alcohol use 1.09 ( 0.75,  1.58 )
Full Modela 1.09 ( 0.84,  1.80 )
Whites
CYP1B1AS 0.90 ( 0.60,  1.35 )
CYP1B1AS, Age 0.91 ( 0.62,  1.32 )
CYP1B1AS, BMI 0.84 ( 0.55,  1.26 )
CYP1B1AS, Smoking 0.90 ( 0.60,  1.35 )
CYP1B1AS, Oral conceptive use 0.91 ( 0.61,  1.38 )
CYP1B1AS, Full term births after age 24 0.90 ( 0.60,  1.35 )
CYP1B1AS, Alcohol use 0.92 ( 0.61,  1.38 )
Full Modela 0.91 ( 0.61,  1.35 )
a
 Full model includes the following variables: COMT genotype, age, smoking, BMI, oral contraceptive use, and 
alcohol use
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Table A.26. Assessment of confounding for the main effects of CYP1B1LV allele and fibroid prevalence among 
African American and White premenopausal women in the Uterine Fibroid Study whose largest fibroid recorded was 
<2cm (small) compared to no fibroids
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1B1LV 0.98 ( 0.71,  1.36 )
CYP1B1LV, Age 1.02 ( 0.74,  1.41 )
CYP1B1LV, BMI 1.02 ( 0.74,  1.40 )
CYP1B1LV, Smoking 0.96 ( 0.69,  1.33 )
CYP1B1LV, Oral conceptive use 0.99 ( 0.72,  1.36 )
CYP1B1LV, Full term births after age 24 1.00 ( 0.72,  1.38 )
CYP1B1LV, Alcohol use 1.01 ( 0.74,  1.40 )
Full Modela 1.03 ( 0.76,  1.39 )
Whites
CYP1B1LV 1.10 ( 0.63,  1.92 )
CYP1B1LV, Age 1.14 ( 0.67,  1.93 )
CYP1B1LV, BMI 1.07 ( 0.61,  1.86 )
CYP1B1LV, Smoking 1.08 ( 0.61,  1.89 )
CYP1B1LV, Oral conceptive use 1.09 ( 0.62,  1.90 )
CYP1B1LV, Full term births after age 24 1.09 ( 0.63,  1.91 )
CYP1B1LV, Alcohol use 1.00 ( 0.58,  1.74 )
Full Modela 1.03 ( 0.62,  1.70 )
a
 Full model includes the following variables: COMT genotype, age, smoking, BMI, oral contraceptive use, and 
alcohol use
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Table A.27. Assessment of confounding for the main effects of CYP1A1*2A allele and fibroid prevalence among 
African American and White premenopausal women in the Uterine Fibroid Study whose largest fibroid recorded was 
>2cm and 4cm (medium) compared to no fibroids
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1A1*2A 0.95 ( 0.78,  1.17 )
CYP1A1*2A, Age 0.98 ( 0.80,  1.19 )
CYP1A1*2A, BMI 1.00 ( 0.82,  1.22 )
CYP1A1*2A, Smoking 0.97 ( 0.79,  1.18 )
CYP1A1*2A, Oral conceptive use 0.97 ( 0.79,  1.18 )
CYP1A1*2A, Full term 0.97 ( 0.79,  1.18 )
CYP1A1*2A, Full term births after age 24 0.98 ( 0.80,  1.19 )
CYP1A1*2A, Alcohol use 0.95 ( 0.77,  1.16 )
Full Modela 1.03 ( 0.85,  1.26 )
Whites
CYP1A1*2A 0.91 ( 0.60,  1.39 )
CYP1A1*2A, Age 0.97 ( 0.65,  1.45 )
CYP1A1*2A, BMI 0.91 ( 0.60,  1.39 )
CYP1A1*2A, Smoking 0.89 ( 0.58,  1.36 )
CYP1A1*2A, Oral conceptive use 0.91 ( 0.60,  1.39 )
CYP1A1*2A, Full term births after age 24 0.93 ( 0.61,  1.41 )
CYP1A1*2A, Alcohol use 0.89 ( 0.48,  1.28 )
Full Modela 0.82 ( 0.52,  1.31 )
a
 Full model includes the following variables: COMT genotype, age, smoking, BMI, oral contraceptive use, and 
alcohol use
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Table A.28. Assessment of confounding for the main effects of CYP1A1*3 allele and fibroid prevalence among 
African American and White premenopausal women in the Uterine Fibroid Study whose largest fibroid recorded was 
>2cm and 4cm (medium) compared to no fibroids
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1A1*3 1.25 ( 0.99,  1.59 )
CYP1A1*3, Age 1.30 ( 1.05,  1.63 )
CYP1A1*3, BMI 1.20 ( 0.95,  1.52 )
CYP1A1*3, Smoking 1.23 ( 0.97,  1.56 )
CYP1A1*3, Oral conceptive use 1.23 ( 0.97,  1.56 )
CYP1A1*3, Full term 1.27 ( 1.00,  1.61 )
CYP1A1*3, Full term births after age 24 1.25 ( 0.98,  1.59 )
CYP1A1*3, Alcohol use 1.29 ( 1.02,  1.63 )
Full Modela 1.22 ( 0.96,  1.55 )
a
 Full model includes the following variables: COMT genotype, age, smoking, BMI, oral contraceptive use, 
fullterm births after age 24, and alcohol use
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Table A.29. Assessment of confounding for the main effects of CYP1B1AS  allele and fibroid prevalence among 
African American and White premenopausal women in the Uterine Fibroid Study whose largest fibroid recorded was 
>2cm and 4cm (medium) compared to no fibroids
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1B1AS 1.03 ( 0.82,  1.29 )
CYP1B1AS, Age 1.05 ( 0.84,  1.31 )
CYP1B1AS, BMI 1.08 ( 0.86,  1.35 )
CYP1B1AS, Smoking 1.02 ( 0.81,  1.29 )
CYP1B1AS, Oral conceptive use 1.05 ( 0.84,  1.32 )
CYP1B1AS, Full term 1.06 ( 0.84,  1.34 )
CYP1B1AS, Full term births after age 24 1.06 ( 0.84,  1.33 )
CYP1B1AS, Alcohol use 1.05 ( 0.83,  1.34 )
Full Modela 1.04 ( 0.92,  1.48 )
Whites
CYP1B1AS 1.04 ( 0.73,  1.47 )
CYP1B1AS, Age 1.05 ( 0.76,  1.46 )
CYP1B1AS, BMI 1.05 ( 0.73,  1.50 )
CYP1B1AS, Smoking 1.04 ( 0.73,  1.47 )
CYP1B1AS, Oral conceptive use 1.03 ( 0.72,  1.46 )
CYP1B1AS, Full term 1.05 ( 0.74,  1.49 )
CYP1B1AS, Full term births after age 24 1.02 ( 0.72,  1.45 )
CYP1B1AS, Alcohol use 1.00 ( 0.69,  1.45 )
Full Modela 1.03 ( 0.74,  1.53 )
a
 Full model includes the following variables: COMT genotype, age, smoking, BMI, oral and contraceptive use
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Table A.30. Assessment of confounding for the main effects of CYP1B1LV  allele and fibroid prevalence among 
African American and White premenopausal women in the Uterine Fibroid Study whose largest fibroid recorded was 
>2cm and 4cm (medium) compared to no fibroids
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1B1LV 0.96 ( 0.79,  1.17 )
CYP1B1LV, Age 0.99 ( 0.81,  1.20 )
CYP1B1LV, BMI 0.98 ( 0.81,  1.19 )
CYP1B1LV, Smoking 0.93 ( 0.77,  1.14 )
CYP1B1LV, Oral conceptive use 0.96 ( 0.79,  1.17 )
CYP1B1LV, Full term births after age 24 0.97 ( 0.79,  1.18 )
CYP1B1LV, Alcohol use 0.98 ( 0.80,  1.20 )
Full Modela 1.00 ( 0.83,  1.20 )
Whites
CYP1B1LV 1.07 ( 0.66,  1.73 )
CYP1B1LV, Age 1.11 ( 0.70,  1.76 )
CYP1B1LV, BMI 1.06 ( 0.66,  1.71 )
CYP1B1LV, Smoking 1.09 ( 0.67,  1.77 )
CYP1B1LV, Oral conceptive use 1.08 ( 0.67,  1.75 )
CYP1B1LV, Full term 1.06 ( 0.66,  1.71 )
CYP1B1LV, Full term births after age 24 1.00 ( 0.63,  1.61 )
CYP1B1LV, Alcohol use 0.96 ( 0.59,  1.55 )
Full Model a 1.01 ( 0.64,  1.62 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI, oral 
contraceptive use, and alcohol use
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Table A.31 Assessment of confounding for the main effects of CYP1A1*2A  allele and fibroid prevalence among 
African American and White premenopausal women in the Uterine Fibroid Study whose largest fibroid recorded was 
4cm (large) compared to no fibroids
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1A1*2A 0.98 ( 0.77,  1.26 )
CYP1A1*2A, Age 0.99 ( 0.80,  1.24 )
CYP1A1*2A, BMI 1.00 ( 0.78,  1.28 )
CYP1A1*2A, Smoking 0.98 ( 0.77,  1.26 )
CYP1A1*2A, Oral conceptive use 0.99 ( 0.77,  1.27 )
CYP1A1*2A, Full term births after age 24 1.00 ( 0.78,  1.28 )
CYP1A1*2A, Alcohol use 0.95 ( 0.74,  1.23 )
Full Modela 0.98 ( 0.85,  1.38 )
Whites 
CYP1A1*2A 0.78 ( 0.40,  1.53 )
CYP1A1*2A, Age 0.83 ( 0.43,  1.61 )
CYP1A1*2A, BMI 0.77 ( 0.39,  1.49 )
CYP1A1*2A, Smoking 0.75 ( 0.38,  1.46 )
CYP1A1*2A, Oral conceptive use 0.78 ( 0.40,  1.53 )
CYP1A1*2A, Full term births after age 24 0.83 ( 0.43,  1.60 )
CYP1A1*2A, Alcohol use 0.73 ( 0.36,  1.48 )
Full Modela 0.80 ( 0.41,  1.57 )
a
 Full model includes the following variables: COMT genotype, age, smoking, BMI, and oral contraceptive use
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Table A.32 Assessment of confounding for the main effects of CYP1A1*3  allele and fibroid prevalence among 
African American and White premenopausal women in the Uterine Fibroid Study whose largest fibroid recorded was 
4cm (large) compared to no fibroids
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1A1*3 1.37 ( 1.03,  1.82 )
CYP1A1*3, Age 1.39 ( 1.12,  1.71 )
CYP1A1*3, BMI 1.35 ( 1.02,  1.79 )
CYP1A1*3, Smoking 1.35 ( 1.02,  1.80 )
CYP1A1*3, Oral conceptive use 1.36 ( 1.02,  1.80 )
CYP1A1*3, Full term 1.41 ( 1.07,  1.85 )
CYP1A1*3, Full term births after age 24 1.38 ( 1.04,  1.82 )
CYP1A1*3, Alcohol use 1.35 ( 1.00,  1.82 )
Full Modela 1.24 ( 0.94,  1.63 )
a
 Full model includes the following variables: COMT genotype, age, births after age 25, smoking, BMI, and 
oral contraceptive use
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Table A.33 Assessment of confounding for the main effects of CYP1B1AS allele and fibroid prevalence among 
African American and White premenopausal women in the Uterine Fibroid Study whose largest fibroid recorded was 
4cm (large) compared to no fibroids
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1B1AS 0.95 ( 0.72,  1.24 )
CYP1B1AS, Age 0.98 ( 0.78,  1.25 )
CYP1B1AS, BMI 0.95 ( 0.73,  1.24 )
CYP1B1AS, Smoking 0.96 ( 0.73,  1.25 )
CYP1B1AS, Oral conceptive use 0.95 ( 0.73,  1.24 )
CYP1B1AS, Full term births after age 24 0.97 ( 0.74,  1.27 )
CYP1B1AS, Alcohol use 1.00 ( 0.75,  1.33 )
Full Modela 0.98 ( 0.74,  1.35 )
Whites
CYP1B1AS 1.10 ( 0.65,  1.88 )
CYP1B1AS, Age 1.11 ( 0.66,  1.87 )
CYP1B1AS, BMI 0.98 ( 0.57,  1.69 )
CYP1B1AS, Smoking 1.11 ( 0.65,  1.89 )
CYP1B1AS, Oral conceptive use 1.08 ( 0.62,  1.85 )
CYP1B1AS, Full term births after age 24 1.16 ( 0.69,  1.95 )
CYP1B1AS, Alcohol use 1.05 ( 0.60,  1.82 )
Full Modela 1.12 ( 0.57,  1.93 )
a
 Full model includes the following variables: COMT genotype, age, smoking, BMI, and oral contraceptive use
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Table A.34 Assessment of confounding for the main effects of CYP1B1LV allele and fibroid prevalence among 
African American and White premenopausal women in the Uterine Fibroid Study whose largest fibroid recorded was 
4cm (large) compared to no fibroids
Variables in model
Prevalence 
Ratio(PR) PR 95% CI
African Americans
CYP1B1LV 0.92 ( 0.72,  1.18 )
CYP1B1LV, Age 1.00 ( 0.80,  1.24 )
CYP1B1LV, BMI 0.93 ( 0.72,  1.18 )
CYP1B1LV, Smoking 0.93 ( 0.72,  1.19 )
CYP1B1LV, Oral conceptive use 0.92 ( 0.72,  1.18 )
CYP1B1LV, Full term births after age 24 0.94 ( 0.74,  1.20 )
CYP1B1LV, Alcohol use 0.91 ( 0.71,  1.18 )
Full Model 0.98 ( 0.79,  1.22 )
Whites
CYP1B1LV 1.09 ( 0.53,  2.28 )
CYP1B1LV, Age 1.15 ( 0.56,  2.35 )
CYP1B1LV, BMI 1.08 ( 0.52,  2.25 )
CYP1B1LV, Smoking 1.10 ( 0.53,  2.31 )
CYP1B1LV, Oral conceptive use 1.12 ( 0.54,  2.34 )
CYP1B1LV, Full term births after age 24 1.07 ( 0.52,  2.19 )
CYP1B1LV, Alcohol use 1.24 ( 0.56,  2.75 )
Full Model (full25pc) 1.02 ( 0.50,  1.35 )
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Table A.35. Prevalence Ratio (PR) and 95% Confidence interval (CI) for the association between fibroid presence and 
interactions of CYP1A1*2A genotype and participant characteristics among African Americans, National Institute of 
Environmental Health Science Uterine Fibroid Study
WT/Wt Wt/Var & Var/Var
Characteristics N (%) PR (95% CI) N (%) PR (95% CI)
Total 354(.) 227(.)
Age
35-39 130(36.72) 89(39.21) 0.87 ( 0.70,  1.08)
40-44 125(35.31) 1.06 ( 0.90,  1.25) 81(35.68) 1.28 ( 0.98,  1.67)
>=45 99(27.97) 1.28 ( 1.11,  1.48) 57(25.11) 1.07 ( 0.82,  1.39)
BMI
Normal 82(23.16) 1.0 65(28.63) 0.87 ( 0.68,  1.12)
Overweight 112(31.64) 1.11 ( 0.92,  1.33) 67(29.52) 1.11 ( 0.81,  1.51)
Obese 160(45.20) 1.11 ( 0.93,  1.31) 95(41.85) 1.21 ( 0.91,  1.61)
Smoking Status
Never Smoked 159(44.92) 1.0 117(51.54) 0.98 ( 0.84,  1.15)
Past Smoker 80(22.60) 1.04 ( 0.89,  1.22) 53(23.35) 1.05 ( 0.82,  1.35)
Current Smoker 112(31.64) 1.06 ( 0.91,  1.22) 56(24.67) 0.91 ( 0.70,  1.19)
Oral Contraceptive Use
Never Used OC 28(7.91) 1.0 20(8.81) 0.86 ( 0.53,  1.39)
Current/Past User Of OC 326(92.09) 1.16 ( 0.88,  1.54) 207(91.19) 1.15 ( 0.70,  1.88)
Number Of Full term Births
None 182(51.41) 1.0 113(49.78) 1.05 ( 0.92,  1.19)
1 115(32.49) 1.02 ( 0.90,  1.17) 65(28.63) 0.77 ( 0.60,  0.99)
2 45(12.71) 0.92 ( 0.75,  1.14) 40(17.62) 1.03 ( 0.77,  1.39)
3 Or More 12(3.39) 0.78 ( 0.48,  1.27) 9(3.96) 0.91 ( 0.42,  1.96)
Number Of Alcoholic Drinks 
per week
Less Than 0.5 179(50.56) 1.0 119(52.42) 0.96 ( 0.83,  1.10)
0.5-2 77(21.75) 0.94 ( 0.80,  1.11) 45(19.82) 0.93 ( 0.69,  1.26)
3-6 38(10.73) 0.90 ( 0.71,  1.14) 27(11.89) 1.31 ( 0.97,  1.78)
7 Or More 34(9.60) 1.17 ( 1.01,  1.36) 24(10.57) 0.82 ( 0.59,  1.14)
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Table A.36. Prevalence Ratio (PR) and 95% Confidence interval (CI) for the association between fibroid presence 
and interactions of CYP1A1*2A genotype and participant characteristics among Whites, National Institute of 
Environmental Health Science Uterine Fibroid Study
Wt/Wt Wt/Var & Var/Var
Characteristics N (%) PR (95%CI) N (%) PR (95%CI)
Total 305(.) 98(.)
Age
35-39 103(33.77) 1.0 34(34.69) 0.66 ( 0.36,  1.21)
40-44 105(34.43) 1.14 ( 0.83,  1.57) 31(31.63) 1.61 ( 0.77,  3.37)
>=45 97(31.80) 1.71 ( 1.30,  2.26) 33(33.67) 1.59 ( 0.82,  3.08)
BMI 
Normal 182(59.67) 1.0 55(56.12) 0.92 ( 0.67,  1.27)
Overweight 71(23.28) 0.92 ( 0.69,  1.24) 24(24.49) 1.27 ( 0.73,  2.19)
Obese 52(17.05) 1.22 ( 0.94,  1.59) 19(19.39) 0.84 ( 0.45,  1.54)
Smoking Status
Never Smoked 180(59.02) 1.0 54(55.10) 1.06 ( 0.78,  1.42)
Past Smoker 106(34.75) 1.08 ( 0.85,  1.36) 33(33.67) 0.78 ( 0.46,  1.33)
Current Smoker 19(6.23) 1.29 ( 0.88,  1.87) 11(11.22) 0.68 ( 0.31,  1.50)
Oral Contraceptive Use
Never Used OC 51(16.72) 1.0 18(18.37) 0.94 ( 0.55,  1.60)
Current/Past User Of 
OC
254(83.28) 0.96 ( 0.72,  1.28) 80(81.63) 1.00 ( 0.55,  1.81)
Number Of Full term 
Births
None 201(65.90) 1.0 55(56.12) 0.93 ( 0.70,  1.23)
1 36(11.80) 0.66 ( 0.42,  1.04) 21(21.43) 1.38 ( 0.70,  2.74)
2 or more 68(22.30) 0.82 ( 0.61,  1.09) 22(19.39) 0.97 ( 0.51,  1.82)
Number Of Alcoholic 
Drinks per week
 Less Than 0.5 50(16.39) 1.0 10(10.20) 0.68 ( 0.25,  1.85)
0.5-2 76(24.92) 1.12 ( 0.76,  1.65) 38(38.78) 1.45 ( 0.49,  4.24)
3-6 79(25.90) 1.38 ( 0.96,  1.97) 23(23.47) 0.95 ( 0.30,  2.95)
7 Or More 80(26.23) 1.12 ( 0.76,  1.65) 18(18.37) 1.82 ( 0.61,  5.38)
129
Table A.37. Prevalence Ratio (PR) and 95% Confidence interval (CI) for the association between fibroid presence 
and interactions of CYP1A1*3 genotype and participant characteristics among African Americans, National Institute 
of Environmental Health Science Uterine Fibroid Study
Wt/Wt Wt/Var & Var/Var
Characteristics N (%) PR (95% CI) N (%) PR (95% CI)
Total 498(.) 83(.)
Age
35-39 193(38.76) 1.0 26(31.33) 0.96 ( 0.70,  1.33)
40-44 179(35.94) 1.14 ( 0.99,  1.31) 27(32.53) 1.21 ( 0.83,  1.75)
>=45 126(25.30) 1.26 ( 1.10,  1.45) 30(36.14) 1.24 ( 0.89,  1.75)
BMI
Normal 127(25.50) 1.0 20(24.10) 1.29 ( 1.00,  1.67)
Overweight 150(30.12) 1.17 ( 0.99,  1.39) 29(34.94) 0.92 ( 0.67,  1.25)
Obese 221(44.38) 1.24 ( 1.06,  1.44) 34(40.96) 0.80 ( 0.58,  1.10)
Smoking Status
Never Smoked 234(46.99) 1.0 42(50.60) 1.21 ( 1.03,  1.42)
Past Smoker 116(23.29) 1.11 ( 0.97,  1.27) 17(20.48) 0.76 ( 0.53,  1.10)
Current Smoker 144(28.92) 1.03 ( 0.90,  1.18) 24(28.92) 1.01 ( 0.79,  1.30)
Oral Contraceptive Use
Never Used OC 43(8.63) 1.0 5(6.02) 1.38 ( 0.83,  2.28)
Current/Past User Of OC 455(91.37) 1.25 ( 0.97,  1.62) 78(93.98) 0.82 ( 0.49,  1.37)
Number Of Full term Births:
None 256(51.41) 1.0 39(46.99) 1.17 ( 1.01,  1.35)
1 154(30.92) 0.93 ( 0.82,  1.06) 26(31.33) 1.00 ( 0.77,  1.29)
2 or more 88(17.68) 0.91 ( 0.78,  1.07) 18(21.69) 0.91 ( 0.64,  1.29)
Number Of Alcoholic Drink per 
week:
 Less Than 0.5 248(49.80) 1.0 50(60.24) 1.16 ( 1.00,  1.34)
0.5-2 105(21.08) 0.90 ( 0.77,  1.06) 17(20.48) 1.17 ( 0.90,  1.53)
3-6 60(12.05) 1.05 ( 0.90,  1.24) 5(6.02) 0.68 ( 0.32,  1.43)
7 Or More 53(10.64) 1.12 ( 0.96,  1.30) 5(6.02) 0.86 ( 0.53,  1.38)
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Table A.38. Prevalence Ratio (PR) and 95% Confidence interval (CI) for the association between fibroid presence 
and interactions of CYP1A1*2C genotype and participant characteristics among Whites, National Institute of 
Environmental Health Science Uterine Fibroid Study
Wt/Wt Wt/Var & Var/Var
Characteristics N (%) PR (95% CI) N (%) PR (95% CI)
Total 363(.) 39(.)
Age
35-39 121(33.3) 1.0 15(38.5) 0.71 ( 0.30,  1.71)
40-44 121(33.3) 1.22 ( 0.89,  1.65) 15(38.5) 1.65 ( 0.60,  4.52)
>=45 121(33.3) 1.91 ( 1.47,  2.48) 9(23.1) 0.87 ( 0.28,  2.74)
BMI
Normal 216(59.5) 1.0 21(53.8) 0.75 ( 0.43,  1.32)
Overweight 84(23.1) 0.94 ( 0.73,  1.23) 10(25.6) 1.39 ( 0.59,  3.31)
Obese 63(17.4) 1.19 ( 0.94,  1.52) 8(20.5) 0.82 ( 0.28,  2.41)
Smoking Status
Never Smoked 212(58.4) 1.0 22(56.4) 0.90 ( 0.56,  1.46)
Past Smoker 127(35.0) 1.04 ( 0.84,  1.29) 12(30.8) 0.70 ( 0.27,  1.81)
Current Smoker 24(6.6) 1.16 ( 0.81,  1.67) 5(12.8) 0.76 ( 0.22,  2.57)
Oral Contraceptive Use
Never Used OC 63(17.4) 1.0 6(15.4) 0.95 ( 0.41,  2.20)
Current/Past User Of OC 300(82.6) 0.98 ( 0.75,  1.27) 33(84.6) 0.80 ( 0.31,  2.07)
Number Of Full term Births:
None 238(65.6) 1.0 17(43.6) 0.74 ( 0.41,  1.32)
1 47(12.9) 0.70 ( 0.48,  1.02) 10(25.6) 1.73 ( 0.69,  4.36)
2 or more 78(21.5) 0.86 ( 0.66,  1.12) 12(30.8) 1.26 ( 0.48,  3.30)
Number Of Alcoholic Drinks per 
week 
Less Than 0.5 55(15.2) 1.0 5(12.8) 0.46 ( 0.08,  2.71)
0.5-2 100(27.5) 1.15 ( 0.80,  1.64) 14(35.9) 1.87 ( 0.28, 12.37)
3-6 92(25.3) 1.34 ( 0.95,  1.90) 10(25.6) 1.12 ( 0.15,  8.47)
7 Or More 92(25.3) 1.18 ( 0.83,  1.70) 5(12.8) 1.69 ( 0.21, 13.61)
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Table A.39. Prevalence Ratio (PR) and 95% Confidence interval (CI) for the association between fibroid presence 
and interactions of CYP1A1*4 genotype and participant characteristics among Whites, National Institute of 
Environmental Health Science Uterine Fibroid Study
Wt/Wt Wt/Var & Var/Var
Characteristics N (%) PR (95%CI) N (%) PR (95%CI)
Total 368(.) 36(.)
Age
35-39 125(34.0) 1.0 12(33.3) 1.42 ( 0.77,  2.62)
40-44 124(33.7) 1.30 ( 0.96,  1.77) 12(33.3) 0.77 ( 0.33,  1.81)
>=45 119(32.3) 1.94 ( 1.48,  2.55) 12(33.3) 0.84 ( 0.42,  1.67)
BMI
Normal 217(59.0) 1.0 20(55.6) 1.07 ( 0.69,  1.68)
Overweight 86(23.4) 0.92 ( 0.71,  1.21) 9(25.0) 1.60 ( 0.87,  2.95)
Obese 65(17.7) 1.19 ( 0.93,  1.53) 7(19.4) 0.91 ( 0.41,  2.05)
Smoking Status
Never Smoked 215(58.4) 1.0 19(52.8) 1.06 ( 0.68,  1.66)
Past/Current Smoker 153(41.6) 1.02 ( 0.82,  1.25) 17(47.3) 1.29 ( 0.72,  2.29)
Oral Contraceptive Use
Never Used OC 64(17.4) 1.0 5(13.9) 0.75 ( 0.25,  2.25)
Current/Past User Of OC 304(82.6) 0.92 ( 0.71,  1.20) 31(86.1) 1.71 ( 0.55,  5.35)
Number Of Full term Births:
None 236(64.1) 1.0 21(58.3) 1.40 ( 1.06,  1.86)
1 50(13.6) 0.76 ( 0.53,  1.09) 7(19.4) 0.75 ( 0.29,  1.96)
2 or More 82(22.3) 0.84 ( 0.65,  1.09) 8(22.3) 0.59 ( 0.23,  1.96)
Number Of Alcoholic Drinks 
per week:
Less Than 0.5 56(15.2) 1.0 4(11.1) 0.58 ( 0.10,  3.27)
0.5-2 103(28.0) 1.10 ( 0.76,  1.58) 12(33.3) 2.65 ( 0.45, 15.61)
3-6 93(25.3) 1.24 ( 0.87,  1.78) 9(25.0) 2.50 ( 0.43, 14.67)
7 Or More 90(24.5) 1.21 ( 0.84,  1.74) 8(22.2) 1.66 ( 0.26, 10.74)
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Table A.40. Prevalence Ratio (PR) and 95% Confidence interval (CI) for the association between fibroid presence 
and interactions of CYP1B1AS genotype and participant characteristics among  African Americans, National Institute 
of Environmental Health Science Uterine Fibroid Study
Wt/Wt Wt/Var & Var/Var
Characteristics N (%) PR (95% CI) N (%) PR (95% CI)
Total 152(.) 425(.)
Age
35-39 63(41.4) 1.0 155(36.5) 0.92 ( 0.75,  1.14)
40-44 50(32.9) 1.11 ( 0.87,  1.40) 153(36.0) 1.08 ( 0.81,  1.43)
>=45 39(25.7) 1.17 ( 0.93,  1.48) 117(27.5) 1.16 ( 0.88,  1.53)
BMI
Normal 35(23.0) 1.0 110(25.9) 0.87 ( 0.68,  1.13)
Overweight 48(31.6) 1.07 ( 0.82,  1.39) 130(30.6) 1.10 ( 0.80,  1.51)
Obese 69(45.4) 1.00 ( 0.77,  1.30) 185(43.5) 1.27 ( 0.93,  1.72)
Smoking Status
Never Smoked 76(50.0) 1.0 199(46.8) 1.06 ( 0.89,  1.26)
Past Smoker 31(20.4) 1.08 ( 0.84,  1.40) 101(23.8) 0.97 ( 0.72,  1.29)
Current Smoker 43(28.3) 1.17 ( 0.94,  1.45) 123(28.9) 0.84 ( 0.65,  1.09)
Oral Contraceptive Use
Never Used OC 10(6.6) 1.0 37(8.7) 0.85 ( 0.52,  1.38)
Current/Past User Of OC 142(93.4) 1.05 ( 0.69,  1.59) 388(91.3) 1.19 ( 0.73,  1.97)
Number Of Full term Births:
None 83(54.6) 1.0 212(49.9) 1.11 ( 0.95,  1.30)
1 48(31.6) 1.10 ( 0.89,  1.35) 128(30.1) 0.81 ( 0.63,  1.04)
2 or More 18(11.8) 1.07 ( 0.80,  1.42) 67(15.8) 0.81 ( 0.63,  1.04)
Number Of Alcoholic Drinks per 
week 
Less Than 0.5 66(43.4) 1.0 230(54.1) 0.99 ( 0.84,  1.16)
0.5-2 32(21.1) 0.83 ( 0.62,  1.13) 88(20.7) 1.15 ( 0.82,  1.61)
3-6 22(14.5) 1.09 ( 0.86,  1.39) 43(10.1) 0.88 ( 0.64,  1.21)
7 Or More 16(10.5) 0.98 ( 0.70,  1.37) 42(9.9) 1.15 ( 0.79,  1.66)
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Table A.41 Prevalence Ratio (PR) and 95% Confidence interval (CI) for the association between fibroid presence and 
interactions of CYP1B1AS genotype and participant characteristics among Whites, National Institute of Environmental 
Health Science Uterine Fibroid Study
Wt/Wt Wt/Var & Var/Var
Characteristics N (%) PR (95%CI) N (%) PR (95%CI)
Total 204(.) 198(.)
Age
35-39 66(32.4) 1.0 70(35.4) 0.91 ( 0.58,  1.43)
40-44 72(35.3) 1.11 ( 0.74,  1.68) 64(32.3) 1.27 ( 0.72,  2.27)
>=45 66(32.4) 1.84 ( 1.30,  2.61) 64(32.3) 1.07 ( 0.65,  1.77)
BMI
Normal 130(63.7) 1.0 106(53.5) 1.13 ( 0.87,  1.47)
Overweight 43(21.1) 0.99 ( 0.69,  1.44) 51(25.8) 0.97 ( 0.59,  1.59)
Obese 31(15.2) 1.58 ( 1.20,  2.09) 41(20.7) 0.55 ( 0.35,  0.88)
Smoking Status
Never Smoked 117(57.4) 1.0 116(58.6) 1.02 ( 0.79,  1.32)
Past Smoker 70(34.3) 1.04 ( 0.77,  1.40) 68(34.3) 0.97 ( 0.64,  1.47)
Current Smoker 17(8.3) 1.19 ( 0.77,  1.84) 14(7.1) 0.95 ( 0.49,  1.84)
Oral Contraceptive Use
Never Used OC 27(13.2) 1.0 42(21.2) 0.79 ( 0.51,  1.25)
Current/Past User Of 
OC
177(86.8) 0.83 ( 0.58,  1.18) 156(78.8) 1.32 ( 0.80,  2.17)
Number Of Full term 
Births:
None 130(63.7) 1.0 126(63.6) 1.10 ( 0.88,  1.38)
1 30(14.7) 0.98 ( 0.66,  1.45) 27(13.6) 0.52 ( 0.25,  1.06)
2 or More 44(21.5) 0.86 ( 0.60,  1.24) 45(22.7) 0.89 ( 0.53,  1.48)
Number Of Alcoholic 
Drinks per week:
Less Than 0.5 36(17.6) 1.0 24(12.1) 1.18 ( 0.65,  2.14)
0.5-2 53(26.0) 1.48 ( 0.93,  2.38) 61(30.8) 0.64 ( 0.32,  1.29)
3-6 46(22.5) 1.31 ( 0.80,  2.17) 56(28.3) 0.98 ( 0.49,  1.98)
7 Or More 53(26.0) 1.36 ( 0.84,  2.21) 44(22.2) 0.82 ( 0.40,  1.67)
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Table A.42. Prevalence Ratio (PR) and 95% Confidence interval (CI) for the association between fibroid presence and 
interactions of CYP1B1LV genotype and participant characteristics among African Americans, National Institute of 
Environmental Health Science Uterine Fibroid Study
Wt/Wt Wt/Var & Var/Var
Characteristics N (%) PR (95% CI) N (%) PR (95% CI)
Total 326(.) 255(.)
Age 
35-39 124(38.0) 1.0 96(37.6) 0.87 ( 0.71,  1.07)
40-44 120(36.8) 1.12 ( 0.95,  1.31) 85(33.3) 1.10 ( 0.85,  1.44)
>=45 82(25.2) 1.18 ( 1.01,  1.39) 74(29.0) 1.26 ( 0.98,  1.61)
BMI
Normal 87(26.7) 1.0 60(23.5) 0.81 ( 0.63,  1.05)
Overweight 91(27.9) 1.07 ( 0.89,  1.28) 88(34.5) 1.24 ( 0.90,  1.69)
Obese 148(45.4) 1.09 ( 0.92,  1.28) 107(42.0) 1.27 ( 0.95,  1.71)
Smoking Status
Never Smoked 163(50.0) 1.0 114(44.7) 1.05 ( 0.91,  1.22)
Past Smoker 72(22.1) 1.15 ( 0.99,  1.34) 61(23.9) 0.83 ( 0.65,  1.07)
Current Smoker 89(27.3) 1.08 ( 0.93,  1.27) 78(30.6) 0.88 ( 0.69,  1.12)
Oral Contraceptive Use
Never Used OC 20(6.1) 1.0 28(11.0) 1.36 ( 0.82,  2.25)
Current/Past User Of OC 306(93.9) 1.51 ( 0.97,  2.35) 227(89.0) 0.71 ( 0.42,  1.19)
Number Of Full term Births:
None 160(49.1) 1.0 136(53.3) 1.06 ( 0.93,  1.21)
1 108(33.1) 1.01 ( 0.88,  1.17) 71(27.8) 0.82 ( 0.64,  1.04)
2 48(14.7) 1.01 ( 0.83,  1.22) 37(14.5) 0.86 ( 0.63,  1.16)
3 Or More 10(3.1) 0.81 ( 0.49,  1.36) 11(4.3) 0.86 ( 0.40,  1.82)
Number Of Alcoholic Drinks per
Week
 Less Than 0.5 159(48.8) 1.0 140(54.9) 0.96 ( 0.84,  1.10)
0.5-2 73(22.4) 0.93 ( 0.79,  1.11) 48(18.8) 0.94 ( 0.70,  1.26)
3-6 38(11.7) 1.00 ( 0.82,  1.22) 27(10.6) 1.02 ( 0.74,  1.40)
7 Or More 33(10.1) 0.99 ( 0.80,  1.23) 25(9.8) 1.22 ( 0.92,  1.62)
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Table A.43. Prevalence Ratio (PR) and 95% Confidence interval (CI) for the association between fibroid presence 
and interactions of CYP1B1LV genotype and participant characteristics among Whites, National Institute of 
Environmental Health Science Uterine Fibroid Study
Wt/Wt Wt/Var & Var/Var
Characteristics N (%) PR (95% CI) N (%) PR (95% CI)
Total 67(.) 337(.)
Age
35-39 20(29.9) 1.0 117(34.7) 1.19 ( 0.59,  2.40)
40-44 23(34.3) 1.38 ( 0.61,  3.09) 113(33.5) 0.91 ( 0.38,  2.16)
>=45 24(35.8) 2.11 ( 1.03,  4.34) 107(31.8) 0.89 ( 0.41,  1.92)
BMI
Normal 41(61.2) 1.0 196(58.2) 0.98 ( 0.70,  1.39)
Overweight 16(23.9) 0.75 ( 0.37,  1.52) 79(23.4) 1.37 ( 0.65,  2.91)
Obese 10(14.9) 1.20 ( 0.66,  2.17) 62(18.4) 0.98 ( 0.52,  1.88)
Smoking Status
Never Smoked 31(46.3) 1.0 203(60.2) 0.96 ( 0.66,  1.39)
Past Smoker 28(41.8) 0.72 ( 0.39,  1.31) 111(32.9) 1.52 ( 0.80,  2.89)
Current Smoker 8(11.9) 1.45 ( 0.86,  2.46) 23(6.8) 0.73 ( 0.37,  1.42)
Oral Contraceptive 
Use
Never Used OC 15(22.4) 1.0 54(16.0) 1.15 ( 0.64,  2.10)
Current/Past User 
Of OC
52(77.6) 1.05 ( 0.57,  1.93) 283(84.0) 0.90 ( 0.46,  1.75)
Number Of Full term 
Births:
None 41(61.2) 1.0 216(64.1) 1.06 ( 0.77,  1.46)
1 9(13.4) 0.85 ( 0.39,  1.86) 48(14.2) 0.86 ( 0.36,  2.04)
2 12(17.9) 0.95 ( 0.50,  1.80) 68(20.2) 0.89 ( 0.44,  1.78)
3 Or More 5(7.5) 0.38 ( 0.06,  2.25) 5(1.5) 0.94 ( 0.08, 11.47)
Number Of Alcoholic 
Drinks per week:
Less Than 0.5
14(20.9) 1.0 46(13.6) 1.22 ( 0.56,  2.65)
0.5-2 18(26.9) 1.24 ( 0.52,  2.98) 97(28.8) 0.93 ( 0.36,  2.42)
3-6 16(23.9) 1.75 ( 0.79,  3.89) 86(25.5) 0.71 ( 0.29,  1.73)
7 Or More 16(23.9) 1.49 ( 0.64,  3.48) 82(24.3) 0.79 ( 0.31,  2.01)
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Figure A.1. Catechol Estrogen Metabolism
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Figure A.2.  Conceptual Model
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Figure A.3 . Location of Val158Met polymorphism on the membrame bound form of the COMT gene.  The shaded boxes represent 
the exons.  
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Figure A.4. Location of CYP1A1*2A, CYP1A1*2C, CYP1A1*3, and CYP1A1*4 on the CYP1A1 gene.  The shaded boxes represent 
the exons.  
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Figure A.5. Location of CYP1B1AS and CYP1B1LV on the CYP1B1 gene.  The shaded boxes represent the exons.  
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